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ABSTRACT 
CD4+ Regulatory T cells (Treg cells) are a specialized subpopulation of T cells that act to 
suppress immune response, thereby maintaining homeostasis and self-tolerance. These cells 
play a critical role in preventing autoimmunity infections, and cancer. Treg cells can infiltrate 
tumor tissues where they suppress anti-tumor immune responses, contributing to the 
development of an immunosuppressive tumor microenvironment thus promoting immune 
evasion and cancer progression. Tumor infiltrating Treg cells can display function 
heterogeneity, depending on both the tumor type and the inflammatory milieu, therefore 
molecular characterization of Treg cells is crucial to understand how these cells can be 
modulated in the tumor to unleash effective anti-tumor T cell responses. To this aim, we 
investigated the transcriptional blueprints of Treg cells both in tumors and in the peripheral 
blood of healthy donors to define both coding and non-coding transcripts that best define the 
identity of these cells and might therefore represent novel prognostic markers or therapeutic 
targets. We performed a transcriptome analysis of both CD4+ Treg cells and effector cells (Th1 
and Th17) infiltrating two of the most frequent types of human cancer defining the molecular 
signatures of tumor-infiltrating Treg cells in these two cancer types. We found tumor-
infiltrating Treg cells were highly suppressive, upregulated several immune-checkpoints, and 
expressed on the cell surfaces specific signature molecules such as interleukin-1 receptor 2 
(IL1R2), programmed death (PD)-1 Ligand1, PD-1 Ligand2, and CCR8 chemokine enriched in 
tumor infiltrating Treg cells compared to both the peripheral blood of patients and healthy 
donors.  
Given the high specificity of long non-coding RNA compared to coding sequences, we also 
performed bioinformatic analysis to assess the expression of known and novel non-coding 
transcripts. With this analysis we identified specific Treg cell non-coding transcript in 
proximity of CTLA4 locus. Since lncRNAs are by now considered as key regulatory elements 
in immune cell differentiation and maintenance of their identity, we characterized the 
identified lncRNAs in Treg cells in healthy donors, defining their epigenetic organization, 
expression level, localization and whether they contributed to the established Treg cell 
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suppressive activity. All these findings unveiled another layer of the complexity of Treg cells 
biology and warrants for more detailed functional studies that can fully explain the pathways 
and the cellular networks that are affected by the identified coding and non-coding transcripts. 
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INTRODUCTION 
1. The immune system    
The immune system has evolved to recognize and eliminate pathogens as well as reduce 
immune–mediated inflammation caused by commensal microorganisms, immune response 
against self and environmental antigens, and metabolic inflammatory disorders.   
In this settings, innate and adaptive immunity, that represent the two main branches of immune 
response, play complementary roles: the innate immune system, also known as non-specific 
immune system, depends on physical epithelial barriers, macrophages, dendritic cells, 
granulocytes and natural killer cells which recognize conserved features of pathogens and 
become quickly activated to help fight pathogens directly at the site of invasion (Stuart E. 
Turvey, MB BS, DPhil and David H. Broide 2006); it initiates a primary response upon 
stimulation by damage (DAMPs, damage associated molecular signals) and pathogen signals 
(PAMPs, pathogen associated molecular patterns) (Kono et al, 2008). In contrast, the adaptive 
immune response is highly specific to different pathogens and is mediated by T and B-
Lymphocytes that are able to recognize foreign antigens in peripheral lymphoid organs, 
carrying receptors with unlimited potential (Bonilla and Oettgen 2010). 
The activation of adaptive immune cells allows affinity maturation and clonal expansion and 
comparing to innate immunity, adaptive immune system is characterized by a “memory 
response” through which immune system cells respond more rapidly and effectively to 
pathogens already encountered, providing long-lasting protection. Another important feature of 
adaptive immune response consists in the discrimination between self and non self, since 
lymphocyte receptor repertoire contains approximately 109 -1015 specificities with potential to 
identify any epitope. This distinction is mediated by two separate mechanisms: central and 
peripheral tolerance. The former occurs in the thymus, where all T-lymphocytes carrying T cell 
receptors with high affinity to self proteins are deleted (Palmer 2003). The latter consists of 
different tolerance mechanisms in which T lymphocytes are deleted because of low levels or 
no accessibility to the antigen (Redmond and Sherman 2005). 
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2. Lymphocytes selection and differentiation 
2.1	T	cell	thymic	development:	positive	and	negative	selection	
T lymphocytes progenitors arise from bone marrow deriving stem cells that migrate to the 
thymus. During their development in the thymus, thymocytes receive strict selection processes 
that only permits T lymphocytes functional TCRs to exit the thymus: less than 5% of 
thymocytes is selected and enable to move to periphery (Starr, Jameson, and Hogquist 2003) . 
Differentiation is characterized by the temporally coordinated expression of cell surface 
proteins on the thymocyte, including CD4, CD8, CD44, and CD25; once into the thymus, the 
precursors lack expression of CD4 and CD8 and are called double negative (DN). They arrive 
in the cortico-medullary junction (CMJ), move through the cortex and sequentially pass 
different stages at the subcapsular zone (Lind et al. 2001) (Fig. 1): 
• DN1 (CD44+/CD25-),  
• DN2 (CD44+/CD25+)  
• DN3 (CD44-/CD25+).   
In this stage, the random recombination of V, D, J genes (or for the α chain, V and J only) 
generates TCR through the enzymatic complex composed of the recombination activating-
genes RAG1 and RAG2 (Starr et al. 2003). The transition of thymocytes from a population of 
cells undergoing TCRβ chain genes to a population enriched in cells with productively 
rearranged TCRβ chain genes is known as "beta selection” (M. Michie et al., 2002). The 
rearranged TCRβ chain together with a pre-TCRα chain forms a pre-TCR complex and 
stimulates thymocyte proliferation, rearrangement of the TCRα chain locus and the induction 
of the two TCR co-receptors CD4 and CD8 (Hoffman et al., 1996).  
Double Positive precursors expressing an MHC Class I– or Class II–restricted receptor migrate 
into the medulla and differentiate into mature T cells. This process is named “positive 
selection” and occurs several days to finalize, during which thymocytes receive continuous 
TCR signals with associated activation of the mitogen activated protein kinase (MAPK) 
pathway in order to pass this checkpoint in development (McNeil et al., 2005; Wilkinson et al., 
1995).  
			 5	
 
Figure 1: αβ chain T cell development. It is reported the different cell surface markers expressed at the different 
stages of T cell development.  
 
The diversity of the TCRs is important for produce protection against an undefined number of 
pathogens, but the TCR rearrangement inevitably generates a certain number of T cells that 
recognize self-antigens. In this case, autoreactive T cells are negatively selected and eliminated 
in the thymic medulla, avoiding self-reactivity and autoimmunity phenomena. This negative 
selection in the thymus represents the major mechanism of central immune tolerance. It is also 
complemented by peripheral mechanisms that limit the expansion and reactivity of mature self-
reactive cells, a phenomenon called peripheral tolerance (Mueller 2010). 
In addition to these “passive” mechanism of controlling self reactive T cells, there is also a 
“dominant” control mechanism in which certain T cells actively downregulate 
activation/proliferation of self reactive T cells: regulatory T cells.  
 
2.2	T	helper	cell	subsets	
In the secondary lymphoid organs, naive CD4+ lymphocytes circulate in searching the of 
antigen presenting APCs: if encountered in the context of co-stimulation and appropriate 
cytokines that get them the necessary stimuli for the differentiation in specialized lymphocytes.  
The major T helper lineages are characterized by T helper type1- Th1- and type 2 -Th2- which 
are involved in promoting cellular and humoral responses, respectively. The other CD4+ 
helper subsets identified during the time are Th9, Th17, T regulatory and T follicular helper 
(Tfh). 
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Th1 cell subset is responsible of cell-mediate immunity and it secretes interferon γ (INFγ), 
Interleukin-12 (IL-12) and tumor necrosis factor (TNF) as the main cytokines and it displays 
on its surface specific markers, including C-X-C Motif Chemokine Receptor 3, (CXCR3) and 
C-C chemokine receptor type 5 (CCR5). INFγ secreted by Th1 induces the activation of 
macrophages, allowing elimination of pathogens, such as viruses and intracellular bacteria. 
There are several transcription factors involved in the full differentiation of Th1 lymphocytes: 
T-box transcription factor (T-bet) is the master regulator and it has a major role in Th1 
development by enhancing the production of INFγ and by inhibiting Interleukin 4 (IL-4) gene, 
GATA binding protein 3 (GATA3) and RORγt thus leading to the suppression of Th2 and 
Th17 lineages (Murphy and Reiner 2002).  
Th2 are mainly involved in the humoral immunity response against extracellular parasites 
through the activation of eosinophils, basophils, mast cells and B cells. Th2 cells differentiate 
upon IL-4 stimulation and they display on their surface the chemokine receptor C-C 
chemokine receptor type 4 (CCR4), which interacts with chemokine ligands CCL17 and 
CCL22 and determines migration oh Th2 cells in inflamed skin (Luckheeram et al. 2012).  
Th17 cells depict the third class of T helper cells that are implicated in the protection against 
extracellular bacteria and fungi infection and they can recruit also neutrophils. Th17 cells are 
characterized by the expression of CCR6 on their surface, which mediates migration to 
inflammatory sites through interaction with CCL20. Their differentiation is enhanced by IL-6, 
TGF-β, IL-23 and IL-21 and they produce IL-17, IL-6, IL-22 and TNF-α. The master regulator 
of Th17 is RORγt (Luckheeram et al. 2012).  
 
Figure 2: CD4+ T helper cell subsets. Naïve T cells are stimulated to expand after the interaction with APCs 
expressing MHC class II/peptide complexes. Depending on the type of APC and the cytokine milieu at the site of 
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antigen encounter, naïve T cells can differentiate into different subsets with different effector functions (O'Shea 
and Paul. 2010. Science) 
 
3. CD4+ T Regulatory cells  
3.1	Phenotype	and	heterogeneity	of	Treg	population	
Regulatory T cells are the primary mediators of “peripheral tolerance” and play out several 
sophisticated mechanisms responsible of the maintenance of immune homeostasis, prevention 
of autoimmunity and moderation of inflammation induced by pathogens and environmental 
insults (Vignali, Collison, and Workman 2009). They are naturally present in the immune 
system and their dysfunction causes fatal autoimmune disease, immunopathology and allergy 
(Sakaguchi, Yamaguchi, Nomura, & Ono, 2008 ; Gavin et al., 2006) . 
They were first characterized by several groups in 2001 as CD4+CD25+ T cells expressing 
high amounts of IL2R- alpha chain (CD25) and possessing suppressor activity (Baecher-Allan 
et al. 2001; Dieckmann et al. 2001). An important advance in the study of Treg cells comes in 
2003 with the identification of a key transcription factor, known as forkhead box P3 (FOXP3) 
that is required for their development, maintenance and function (Shohei Hori , Takashi 
Nomura and Shimon Sakaguchi ). However, it has been shown that both CD25 and FOXP3 
expression could be induced in naive CD4+ cells upon activation, obscuring the identification 
of FOXP3 as pure marker of Treg (Gavin et al. 2006). Other Treg cell markers were 
discovered over the time: the cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152), the 
glucocorticoid-induced tumor necrosis factor receptor (GITR) and inducible T factor 
costimulator (ICOS) as well as programmed-death-1 (PD-1); they were found to be expressed 
on human Treg, but neither was specific for Treg (Fife and Bluestone 2008)(Strauss et al. 
2008). Similarly, the chemokine receptors CCR4 (CD194) CCR6 (CD196) and CCR7 
(CD197) which are expressed by human Treg are also found on other T cells (Mougiakakos et 
al. 2010). Treg are also characterized by the absence of certain surface markers that are 
expressed on Tconv such as IL-7-receptor, CD127 (Liu et al. 2006) and an integrin alpha 
subunit, CD49d (Kleinewietfeld et al. 2009).  
Several discrepancies in the literature have emerged during the time regarding the phenotypic 
and functional characterization of Treg cells in healthy individuals and patients with 
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immunological disease, thus requiring new studies for reliable delineation of human Treg cells 
biology and phenotype. 
 
3.2	Thymic	and	peripheral	origins	of	treg	cells		
CD4+ CD25+ Foxp3+ Treg cells, which account for 10% of peripheral CD4+ cells, are 
subdivided into two subset: “natural” Treg (nTreg) and “induced” Treg (iTreg) cells. nTreg 
cells develop as a distinct lineage in the thymus during the course of positive and negative 
selection upon high-avidity interactions with peptide class II major histocompatibility 
complex, while iTreg cells arise from periphery upon Naive CD4+ T cell interaction with 
antigen-presenting cells (APC) (Quezada et al. , 2013). 
A thymic origin for Treg cells was suggested by the neonatal thymectomy–induced 
autoimmunity models (Takahashi et al. 1998). Thymic development of Treg cells requires 
high-affinity interactions between their T cell receptor (TCR) and self-peptide-MHC 
complexes presented by thymic stromal cells (Hinterberger et al. 2010) These cells also 
provide co-stimulatory signals required for Treg cell lineage development as shown by the 
decrease in the number of Treg cells generated in the thymus following loss of CD40 or CD28 
expression (Salomon et al. 2000). Another signal that is necessary for Treg cells differentiation 
is represented by IL-2: mice deficient in IL-2 or CD25 showed a 50% decrease in the 
proportion and absolute numbers of Foxp3+ cells (Fontenot et al. 2005). Regarding the role of 
IL-2 and TCR strength, a “two-step model” for thymic Treg cell differentiation has been 
proposed: high functional avidity TCR signals result in CD25 upregulation and a subsequent 
increase responsiveness of Treg precursors to IL-2 signals facilitate Foxp3 induction (Burchill 
et al. 2008). The peripheral pool of Treg cells not only includes those differentiated in the 
thymus but also Treg cells generated extra-thymically through the “conversion” of naïve 
precursors in the periphery (iTreg). Two main subsets of iTreg cells have been described based 
on the cytokines they produce and that their induction provoke: type 1 regulatory T cells (Tr1), 
which are induced by IL-10 (Vieira et al. 2004) and T helper 3 (Th3) cells, which are induced 
by TGF-β (Weiner 2001). Both subsets exert their suppressive activity trough secretion of the 
same cytokines that are responsible for their induction, IL-10 and TGF-β respectively. Since 
there are not phenotypic markers to distinguish peripherally-induced (iTreg) from thymically 
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derived natural Treg cells (nTreg), the question is whether nTreg and iTreg cells have the same 
or distinct functions. The finding that the requirements for the induction of Foxp3 in the 
thymus and periphery are distinct, suggests that the function of these two Treg cell subsets, 
nTreg and iTreg cells, are also distinct. iTreg cells are thought to be an important population in 
the gut mucosa to maintain tolerance to commensal flora and food antigens (Lathrop et al. 
2011); they are also found within the tumor microenvironment and chronic inflammatory site 
and are important for the maintenance of immune tolerance at mucosal surfaces (Abdel-Gadir, 
Massoud, and Chatila 2018) (Fig. 2). 
 
 
Figure 2: Development of nTreg and iTreg with their associated markers (C. Workman et al. 2009) 
 
3.3	Mechanisms	of	Treg	function		
The definition of Treg cell function mechanism is crucial to provide insight into the control 
processes of peripheral tolerance and to indicate important therapeutic targets. In vitro studies 
have shown that Tregs cells require both TCR stimulation and costimulation to exert their 
suppressive activity, however, once activated, Treg population is non-specific in its 
suppression (Sakaguchi 2004).  
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From a functional perspective, the suppression mechanisms of Treg cells can be grouped in 
four different modes of action (Fig. 3):  
• Suppression by inhibitory cytokines 
• Suppression by cytolysis 
• Suppression by metabolic disruption 
• Suppression by modulation of dendridic cell (DC) maturation or function 
 
 
Figure 3: Mechanisms of Treg cells action arranged into four basic modes of action (C. J. Workman et al. 
2009). 
 
Suppression by inhibitory cytokines 
The secretion of inhibitory cytokines such as IL-10 and TGFβ and IL-35 can inhibit the local 
immune response by acting on target cells such as APCs or T cells, and represent a cell-cell 
contact indipendent effector mechanism (Nakamura, Kitani, and Strober 2001). IL-10 has been 
described as the main immunomodulatory cytokine that additionally inhibits the production of 
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inflammatory cytokines such as IL-12, causing a decrease in the Th1 response and in INF-γ 
production and promoting the phagocytic activity (Loebbermann et al. 2012). One of the best 
known molecular mechanisms of IL-10 is the action on effector cells. The costimulatory 
molecule CD28 is involved in the interaction between effector cells and antigen-presenting 
cells. By binding its receptor, IL-10 inhibits tyrosine phosphorylation in CD28, inhibiting 
PI3K/AKT activation, which in turn inhibits the signaling cascade leading to NF-κB 
translocation (Taylor et al. 2006). TGFβ is able to regulating the effect of several immune cell 
types: it suppresses effector T cell differentiation; it promotes the differentiation of naïve T 
cells into regulatory T or Th17 cells; it inhibits T and B cell proliferation; it inhibits the 
activity of macrophages, dendritic cells, and NK (Ma et al. 2014). In Treg cells, the inhibitory 
activity of TGFβ is due to the high LAP (Latency-Associated Peptide, necessary for activation 
of TGFβ)-TGFβ expression in Treg membrane. Unlike T cells, monocytes and dendritic cells 
express TGFβ receptors, thus allowing for cell-to-cell interaction. Additionally, TGFβ 
regulates dendritic cell maturation and differentiation. TGFβ has been demonstrated as 
necessary to generate tolerogenic dendritic cells (DCs) by inducing IDO, an enzyme that 
inhibits T cell proliferation. 
IL-35 is responsible of suppressing cell proliferation, blocking the shift to a Th1 profile, and 
mediating IL-10 production (Li et al. 2014).  
Although the general importance of IL-10 and TGFβ as suppressive mediators is undisputed, 
their contribution to the function of thymus-derived nTreg cells is still a matter of debate 
(Shevach et al. 2006). This is partly due to the general perception that Treg cells work in a 
contact dependent manner (Takahashi et al. 1998) Indeed, in vitro studies using neutralizing 
antibodies or T cells that are unable to produce or respond to IL-10 and TGFβ suggested that 
these cytokines may not be essential for Treg -cell function (Jonuleit et al. 2001). However, 
this contrasts with data from in vivo studies in which, in allergy and asthma models, Treg cells 
are able to control disease in a manner IL-10 and TGFβ dependent (Hawrylowicz and O’Garra 
2005): adoptive transfer of allergen-specific Treg cells induced significant IL-10 production by 
CD4+ effector T cells in the lung following allergen challenge and this Treg cell-mediated 
control of disease was reversed by treatment with an IL-10-receptor-specific antibody (Kearley 
et al. 2005). 
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Suppression by cytolysis 
Cytolysis mediated by secretion of granzimes had been considered the mileu stone of Natural 
killer cells (NK) and CD8+ cytotoxic T lymphocytes (CTLs)(Lieberman 2003). Indeed, Treg 
cells have been shown suppressive function through production of Granzime B and perforin 
(Grossman et al. 2004). Granzime B is a serine protease which allows Treg cells to induce 
apoptosis in effector T cells (Gondek et al. 2005). During the interaction between Treg cells 
and T effector cells, Treg cells produce granules to the extracellular space that contain 
granzymes and perforins. Once released from Treg cells, perforin molecules insert themselves 
into the lipid membrane of the target cell and polymerize in the presence of calcium ions to 
form a transmembrane cylinder, that, in turn, forms a pore through which granzymes enter the 
cell. Once within the target cell, Granzyme B could induce apoptosis by caspase-dependent or 
independent mechanisms (MacDonald et al. 1999). 
Moreover, recent studies have suggested that activated Treg cells induce apoptosis of effector 
T cells through TRAIL-DR5 pathway (tumor necrosis factor related apoptosis inducing ligand-
death receptor 5)(Ren et al. 2007) and upregulate galectin-1 (also known as LGALS1) which 
can induce T cell apoptosis (Garin et al. 2007). However, all these studies emphasize that more 
work is required to define the cytolytic mechanism that Treg cells use to mediate suppression. 
 
Suppression by metabolic disruption 
The ‘metabolic disruption’ is another mechanism described to suppress effector T-cells in 
which the high expression of CD25 empowers Treg cells to ‘consume’ local IL-2 and could 
starve actively dividing effector T cells by depleting the IL-2 they need to survive (de la Rosa 
et al. 2004). IL-2 receptor is expressed by T lymphocytes, NK cells, B cells, macrophages, and 
monocytes; however, only T lymphocytes are capable of producing this cytokine (Bayer, 
Pugliese, and Malek 2013). IL-2 receptor consists of three subunits: alpha chain (CD25), beta 
chain (CD122), and gamma chain (CD132). Alpha chain (IL-2Rα) has a very short 
cytoplasmic domain and does not participate in signal transduction but it is required to increase 
the affinity of IL-2 to its receptor. In contrast, beta (IL-2Rβ) and gamma (IL-2Rγ) chains are 
responsible of signal transduction (Manuscript and Nanobiomaterials 2013). Treg cells 
constitutively express high levels of IL-2 alpha chain, having thus a higher affinity to IL-2, and 
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compete for this growth factor with proliferating cells leaving them without a vital cytokine, 
causing metabolic interruption and cell death (Burchill et al., 2007).  
Moreover, several evidences have shown another mechanism by which Treg cells suppress 
effector T cells: the release of adenosine nucleotides that inhibit IL-6 expression while 
promoting TGFβ secretion (Zarek et al. 2014). Treg cells were also shown to suppress effector 
T-cell function directly by transferring the potent inhibitory second messenger cyclic AMP 
into effector T cells via membrane gap junctions (Bopp et al. 2007).  
 
Suppression by modulation of dendridic cell (DC) maturation or function 
Studies in vivo have revealed direct interactions between Treg cells and Dendritic Cells in a 
process that involve CTLA4, which is constitutively expressed by Treg cells (Read, 
Malmström, and Powrie 2000). By using either CTLA4-specific blocking antibodies or 
CTLA4-deficient Treg cells it was shown that in the absence of functional CTLA4, Treg -cell-
mediated suppression of effector T cells via DCs was compromised (Oderup et al. 2006). 
Importantly, it was also shown that Treg cells could condition DCs, through a mechanism 
dependent on interactions between CTLA4 and CD80 and/or CD86, to express indoleamine 
2,3-dioxygenase (IDO), a potent regulatory molecule that induces the catabolism of tryptophan 
into pro-apoptotic metabolites that results in the suppression of effector T cells (Mellor and 
Munn 2004). There are also other studies suggesting that LAG3, lymphocyte activation gene 3, 
could block DC maturation. LAG is a CD4 homologue that binds MHC class II molecules with 
very high affinity and provokes immunoreceptor tyrosine-besed activation motif (ITAM) that 
suppresses DC maturation and their immunostimulatory capacity (Liang et al. 2008).  
Cell-to-cell contact with DCs is one of the most important mechanisms for Treg cells mode of 
action. Depending on its phenotype, a DC can activate or control the immune response. When 
DC interacts with a Treg cell, it acquires a tolerogenic phenotype, which in turn promotes 
further Treg cell generation, providing a suppressor microenvironment. The competition for 
DC ligands between effector and Treg cells allows for an additional control mechanism of the 
immune response.  
As discussed above, the mechanisms underlying Treg cells function are mediated by different 
factors but have the same objective: preserving homeostasis and thus guaranteeing the 
establishment of a fine equilibrium across all immune cells. In disease, and in particular in 
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cancer, Treg cell phenotype and function change, therefore this equilibrium is compromised, 
favoring the development of pathologic status. 
 
4. Immunoediting  
The immune surveillance theory was suggested more that 50 years ago by Burnet and Thomas 
and claims that the immune system is considered as a sentinel that recognizes and eliminates 
continuously arising, transformed cells (Burnet 1957). Over the time, this concept has evolved 
in a larger and more complex “cancer immunoediting“ model, whereby the immune system not 
only protects against cancer development, but also it’s responsible of the development of 
tumors (Dunn et al. 2002). Indeed, a central principle of cancer immunoediting is that T cell 
recognition of tumor antigens determines the immunological elimination or allows cancer 
development.  
This process is constituted by three key events (Fig. 4):  
•  Elimination phase: elements of the immune response recognize and destroy tumors.  
• Equilibrium phase: a balance is established between the tumor and the immune system. 
Tumors and immune cells are shaped reciprocally by each other.  
• Escape phase: the immune system allows tumor variants to survive and to grow 
uncontrollably(Koebel et al. 2007).  
 
Elimination 
The elimination phase is constituted by the cooperation of innate and adaptive immune 
responses to transformed cells. The effector cells of the innate response, such as NK, NKT and 
gamma-delta T cells are activated by inflammatory cytokines released by growing tumor cells, 
macrophages and stromal cells located around the tumor. Perforin-, FasL- and TRAIL-
mediated killing of tumor cells by Natural Killer cells releases tumor antigens (TAs), 
stimulating the adaptive immune response (Mori et al. 1997), in particular promoting the 
maturation of DCs and their migration to tumor draining lymph nodes (TDLNs), resulting in 
the enhancement of antigen presentation to naive T cells and the clonal expansion of Citotoxic 
T Lymphocytes (CTLs). They migrate to the primary tumor site and directly kill cancer cells 
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by producing INF-g, a cytokines that induces apoptosis (Wall et al. 2003), antiproliferative 
(Gollob et al. 2005) and anti-angiogenic effects (Qin et al. 2003).  
 
Equilibrium 
It is during the equilibrium phase that the interplay between immune system cells and the 
tumor will define the final outcome of the immune response. Tumor cells continuously 
produce variants that are less immunogenic and the immune selection pressure also favors the 
growth of tumor cell clones with a non-immunogenic phenotype that survive and grow in the 
tumor microenvironment. Since the equilibrium phase involves the continuous elimination of 
tumor cells and the production of resistant tumor variants by immune selection pressure, it is 
likely that equilibrium is the longest of the three processes in cancer immunoediting and may 
occur over a period of many years.  
It is now clear that as tumors develop they can be infiltrated by different subsets of effector, 
helper and regulatory T cells (Treg) which, together with myeloid derived suppressor cells 
(MDSC), can shape the microenvironment into one less permissive for effector T cell function. 
Furthermore, transition through the equilibrium phase not only depends on the extrinsic control 
exerted by Treg cells and MDSC but also on the intrinsic regulation of T cell function by co-
inhibitory and co-stimulatory receptor ligand pairs (Dunn et al. 2002). Understanding the key 
factors involved in maintaining the balance during the Equilibrium phase and recognizing 
ways to interfere with them will help us devise new therapeutic strategies capable of tilting this 
balance towards elimination instead of escape. 
 
Escape  
Tumor cells surviving the equilibrium phase get into the escape phase unstrained by immune 
pressure. 
Progression from equilibrium to the escape phase can occur because the tumor cell population 
changes in response to the immune system’s editing functions and/or because the host immune 
system changes in response to increased cancer-induced immunosuppression or immune 
system deterioration. Tumor cell escape can occur through many different mechanisms: at the 
tumor cell level, alterations such as a loss of antigens or increased resistance to the cytotoxic 
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effects of immunity, for example, through induction of anti-apoptotic mechanisms, promote 
tumor outgrowth.  
Loss of tumor antigen expression is one of the best-studied escape mechanisms, and it can 
occur in at least three ways:  
• through emergence of tumor cells that lack expression of strong rejection antigens,  
• through loss of major histocompatibility complex (MHC) class I proteins that present 
these antigens to tumor-specific T cells,  
• through loss of antigen processing function within the tumor cell that is needed to 
produce the antigenic peptide epitope and load it onto the MHC class molecule. 
All of these alterations are probably driven by a combination of genetic instability inherent in 
all tumor cells and the process of immune-selection (Hung T. Khong and  Nicholas P. Restifo, 
2009). The final outcome is the generation of less immunogenic transformed cells that aren’t 
recognized by immune system and thus acquire the capacity to grow uncontrollably. 
Another escape mechanism consists in the establishment of an immunosuppressive state within 
the tumor microenvironment (Radoja et al. 2000): tumor cells can contribute to the 
development of such a state by producing immunosuppressive cytokines and by recruiting 
regulatory immune cells that are responsible of an immunosuppressive condition (Vesely et al. 
2011).  
 
Figure 4: The Three Phases of the Cancer Immunoediting Process. In the first phase of elimination, cells and 
molecules of innate and adaptive immunity are able to eradicate the developing tumor and to protect the host from 
tumor formation. However, tumor cells get into the equilibrium phase where they are maintained chronically or 
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immunologically sculpted by immune “editors” to produce new tumor variants. These variants may eventually 
evade the immune system by a variety of mechanisms and become clinically detectable in the escape phase 
(Dunn, Old, and Schreiber 2004) 
 
4.1	Role	of	Treg	cells	in	cancer	immunity		
Human tumors are immunogenic and are known to produce a broad variety of 
immunosuppressive factors such as adenosine (Hoskin et al. 2008), prostaglandine  E2 (PGE2) 
(Wang and Dubois 2011), inhibitory cytokines including TGFb (Chen and Konkel 2010),  
gangliodide (Sa et al. 2009) and many others (Gabrilovich et al. 1998). 
Immune cells, including cytotoxic T lymphocytes (CTL), are expected to recognize and 
eliminate tumor cells, indeed they are recruited to tumor site by chemokines and cytokines 
secreted by the various cells in the tumor milieu (Whiteside 2013) but, unfortunately, they are 
rendered dysfunctional (Kim et al. 2006).   
In the tumor microenvironment Treg cells play a critical role in the evolution on tumor 
progression. They are found to infiltrate head and neck (Schaefer et al. 2005), lung (Wolf et al. 
2003), liver (Ormandy et al. 2005), gastrointestinal tract (Sasada et al. 2003), breast and 
pancreas (Liyanage et al. 2002), ovary (Curiel et al. 2004) cancers and their infiltration is 
around 20-30% of total CD4+ cells (Zou 2006). 
While an abundance of TIL (Tumor Infiltrating Lymphocytes) was considered initially a 
marker of good prognosis (Clemente et al. 1996), it is now accepted that it is rather the balance 
between Teff and Treg populations that determines the final outcome (Sato et al. 2005). 
Indeed, an incrementation of Treg cells despite Teff in tumors is correlated with poor 
prognosis in various types of cancers such as breast (Bates et al. 2006) and Non Small Cell 
Lung Cancer (Nguyen et al. 2016). However, there are many controversial debates about the 
role of Treg infiltration in ColoRectal Cancer, CRC: if on one hand, a low ratio between 
Teff:Treg is associated with reduced patient survival time (Sinicrope et al. 2009), on the other 
hand high concentration of Tregs within tumor is correlated with a more favorable clinical 
outcome (Hu, Li, and Wang 2017). Moreover, more recently, Saito et al., showed that CRC 
can be classified in two types by the degree of the additional infiltration of FOXP3lo non-
suppressive T cells, which don’t express Naive T cell marker CD45RA and are characterized 
by instability of FOXP3 and secrete inflammatory cytokines. Indeed, CRCs with abundant 
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infiltration of FOXP3lo T cells showed significantly better prognosis than those with 
predominantly FOXP3hi Treg cell infiltration (Saito et al., 2016).   
 
4.2	Mechanisms	through	which	Treg	cells	infiltrate	within	tumors	
The processes that contribute to Treg accumulation in tumor can be divided into three modes 
of accumulation:  
• Increase trafficking: Treg cells exhibit an enhanced capacity of infiltration and 
accumulation in comparison to Teff. Several chemokines and their receptors are 
implicated in this process: chemokine receptor CCR4 and CCR8 are expressed by Treg 
cells and their ligand CCL22 has been shown to be produced by ovarian (Curiel et al. 
2004) and breast carcinoma (Gobert et al. 2009)and Tumor-infiltrating macrophages 
(Nizar et al. 2009). Blockade of CCL22 reduced Treg cells infiltration into ovarian 
tumors and induced tumor rejection in a murine xenograft model (Curiel et al. 2004). 
Another chemokine, CCL28 can be expressed by tumor during hypoxia, and it’s reported 
to recruit preferentially Treg expressing CCR10 (Facciabene et al. 2011);  
• Preferential Treg expansion: both in situ or in TDLNs, it has been reported that IL-2 
produced by Teff within tumor stimulates the proliferation of Treg cells and Ki-65, a 
marker expressed by proliferative cells, has been observed in tumor infiltrating Treg cells 
(Quezada et al. 2011). Other evidences regarding preferential Treg cell proliferation 
come from TGF-b produced by DC that stimulate Treg expansion within TDLNs in 
rodent tumor models (Ghiringhelli et al. 2005); 
• De novo conversion of conventional CD4+ T cells into iTreg cells: some studies suggest 
that the immunosuppressive potential of Tregs mostly derives from the conversion of 
conventional CD4+ T cells into iTregs in situ, (Zhou and Levitsky 2007), but other 
studies suggested that the predominant mechanism of accumulation is due to nTreg 
(Elkord et al. 2011). Nonetheless, the contribution of iTreg versus nTreg is still 
controversial because no surface marker has been identified to distinguish nTreg from 
iTreg, so far. One possible way to gather information about the origin of Treg cells 
consists in the analysis of the T-cell receptor repertoire. One study based on the chemical 
carcinogen methylcholanthrene (MCA) has demonstrated that Tregs isolated from tumor 
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tissues present a TCR repertoire that is well distinct from that of naïve CD4+ T cells. The 
hypothesis underlying this study was that if Tregs in the tumor truly derived from 
conventional CD4+ T cells, then the overlap between the TCR repertoire of these two 
cell subsets would have been higher. They demonstrated that the tumor infiltrating Treg 
cells originate from nTreg cells because TCR repertoires of Treg and Tconv cells within 
tumor-infiltrating lymphocytes (TILs) are largely distinct and the conversion of Tconv 
cells does not contribute significantly to the accumulation of tumor-infiltrating Tregs; 
rather, Tconv and Treg cells arise from different populations with unique TCR 
repertoires (Hindley et al. 2011). However, results from another study analyzing the 
transgenic TCR repertoire in mice bearing B16 melanoma demonstrate that most 
intratumoral Tregs are generated by the conversion of Teffs (Kuczma et al. 2010). Thus, 
the relative contribution of these two Treg subsets to tumor immune escape is likely to 
depend, at least in part, to the features of the tumor microenvironment they are expose to. 
 
5. Immunotherapy: targeting Treg cells in cancer 
Immunotherapy represents a viable and powerful approach to cancer treatment that potentiates 
the anti-tumor immune-response rather than targeting cancer cells. Since Tregs are involved 
critically in promoting the tumor development by preventing optimal function of effector cells, 
Treg depletion or their suppressive functions manipulation have been increasingly investigated 
as therapeutic strategies. A lot of evidences in literature deal with various methods for Treg 
depletion (Colombo and Piconese 2007). Indeed, Treg cells express surface molecules that can 
be specifically targeted by antibodies or pharmacologic inhibitors such as CTLA-4, GITR, 
CCR4, PD-1, OX-40, and LAG3 that potentially could be targeted in order to deplete Treg 
cells or impair their suppressor functions.  
For this purpose, there are several ways to target Treg cells in cancer: 
• Checkpoint blockade antibody with possible Treg-depleting effects. In the case of T cells, 
the quality of the response, which is initiated through antigen recognition by the T cell 
receptor (TCR), depends on a balance between co-stimulatory and inhibitory signals, 
called immune checkpoints, which are dysregulated by tumors as an important immune 
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resistance mechanism (Pardoll, 2012); thus, blocking of immune checkpoints may 
improves the antitumor immune response that could be a primary goal of cancer 
treatment (Sharma and Allison, 2015; Zitvogel et al., 2013). The two most studied 
immune-checkpoint receptors in the context of clinical cancer immunotherapy are 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; also known as CD152) and 
programmed cell death protein 1 (PD1; also known as CD279), which are both inhibitory 
receptors that are able to regulate immune responses at different levels and by different 
mechanisms (Fig. 5). CTLA-4 is expressed exclusively on T cells and contrasts the 
activity of the T cell co-stimulatory receptor CD28 in binding CD80 and CD86 
molecules, delivering inhibitory signals to the T cell (Egen and Allison 2002). Even 
though CTLA4 is expressed by activated CD8+ effector T cells, the major physiological 
role of CTLA4 has distinct effects on the two major subsets of CD4+ T cells: down-
modulation of helper T cell activity and enhancement of regulatory T (Treg) cell 
immunosuppressive activity (Peggs et al. 2009). Thus, in considering the mechanism of 
action for CTLA4 blockade, both enhancement of effector CD4+ T cell activity and 
inhibition of Treg cell-dependent immunosuppression are probably important factors, 
since Treg cell-specific CTLA4 knockout or down-modulation significantly inhibits their 
ability to regulate both autoimmunity and antitumor immunity (Kajsa, Onishi, and 
Prieto-Martin 2008). Anti-CTLA-4 monoclonal antibodies, such as Ipilimumab, (mAb) 
show remarkable success in metastatic melanoma, and more recently in non-small-cell 
lung cancer, prostate cancer, renal cell carcinoma, urothelial carcinoma and ovarian 
cancer. However, patients show no reduction in Treg numbers or in their suppressive 
capacity, speculating that the effect of anti-CTLA-4 treatment is due to increased 
activation of Teff (Maker, Attia, and Rosenberg 2006). Recent experimental evidence 
shows that anti-CTLA-4 mAb efficacy depends on FcγR mediated depletion of CD4+ 
regulatory T cells within the tumor microenvironment (Peggs et al., 2009; Selby et al., 
2013; Simpson et al., 2013; Twyman-Saint Victor et al., 2015). 
• Programmed death 1 (PD-1) is another widely studied immune checkpoint receptor 
expressed by activated T cells, and it mediates immunosuppression. PD-1 functions 
primarily in peripheral tissues, where T cells may encounter the immunosuppressive PD-
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1 ligands PD-L1 and PD-L2 which are expressed by tumor cells, stromal cells, or both 
(Freeman et al. 2000). Inhibition of the interaction between PD-1 and PD-L1 can enhance 
T-cell responses in vitro and mediate preclinical antitumor activity (Clinic 2002), but it 
remains to be elucidated whether anti-PD-1 antibody (Nivolumab) causes selective 
depletion of Treg cells in tumor tissues (Tanaka and Sakaguchi 2017). 
 
 
Figure 5: Simplified concept of CTLA-4 and PD-1 immune checkpoints. In the first phase, antigen-presenting 
cells present antigens to the T-cell. Two signals are essentials to initiate a T-cell response. CTLA-4 is upregulated 
after T-cell activation and inhibits the T-cell response. Anti-CTLA-4 antibodies bind to CTLA-4, turning off the 
‘inhibitory signal’, thus resulting in an enhancement of T-cell function. In the effector phase, the PD-1 inhibitory 
receptor is expressed by the T-cell and, when it is engaged by its ligands PD-L1 and PD-L2, it is able to inhibit 
the T-cell response. Anti-PD-1 antibodies bind to PD-1, turning off the ‘inhibitory signal’ in the peripheral tissues 
and enhancing T-cell function (Dunn et al. 2004). 
 
Cancer immunotherapies focusing on CTLA-4 and PD-1 blockade are frequently related to 
serious autoimmunity (Hodi et al. 2010). In general, the effectiveness of anti-tumor responses 
tends to correlate with the development of autoimmune diseases especially when a systemic 
Treg cell depletion approach occurs (Callewaert et al. 2012). However, these cell surface 
molecules are peculiar of an activated phenotype of effector Tcells, thus constituting an 
obstacle for specific depletion of Tregs. Therefore, the molecular characterization of Treg cells 
at different tumor sites should help to better define therapeutic targets through a better 
knowledge of their signature molecules and of the network that regulates Treg cell functions in 
the tumor microenvironment. 
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• Depletion of effector Treg cells in tumor tissues. In various cancers effector Treg cells 
are the most abundant cell type among FOXP3+T cells. In order to distinguish and 
selectively deplete tumor-infiltrating Treg cells while preserving other Treg cells 
important for suppressing autoimmunity, one strategy is to specifically target effector 
Treg cells, which are highly activated and proliferative (Zou 2006). Since effector Treg 
cells are a substantial population in tumor tissues, depleting effector Treg cells would 
shift the balance in tumor microenvironment from immune suppression to immune 
activation against tumor cells. For this purpose, surface molecules expressed specifically 
or selectively on effector Treg cells are good targets. For example, CCR4 is 
predominantly expressed by effector Treg cells, not by naive Treg cells and Th2 cells 
which do not contribute significantly to tumor immunity regulation in humans 
(Sugiyama et al. 2013). As discussed above, one of the mechanism through which Treg 
cells infiltrate within the tumor consists of the expression of CCR4 ligands, CCL17 and 
CCL22, produced by tumor cells or infiltrating macrophages (Faget et al. 2011). In vitro 
depletion of CCR4+ T cells significantly reduced tumor-infiltrating Treg cells indicating 
that anti-CCR4 mAb treatment is able to selectively deplete effector Treg cells 
infiltrating into tumors (Sugiyama et al. 2013) (Fig. 6). 
 
 
Figure 6: Treg cells suppress antitumor immune responses. CCL22 produced by tumors and tumor infiltrating 
macrophages recruit CCR4- expressing Treg cells (Treg migration). Treg cells accumulated via CCR4-CCL22 
recognize tumor self-antigens (self-Ag) and proliferate (Treg expansion). Tolerogenic dendritic cells (DCs) 
induced by TGF-b derived from tumor cells further enhances Treg expansion. These Treg cells suppress 
antitumor effector cells (Nishikawa and Sakaguchi 2010) .  
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• Agonistic antibody affecting Treg suppression. GITR is another molecule that is expressed 
preferentially by Treg cells compared to Tconv cells. In tumor- bearing mice, it has been 
shown that agonistic anti-GITR antibody can affect suppressive function mediated by Treg 
cells and evoke potent anti-tumor immune response with an increase in the production of IFN-γ 
by CD8+ and CD4+ T cells, which are able to kill established tumors (Ko et al. 2005). The 
agonistic antibody for GITR is under clinical trials to test its efficacy in melanoma and other 
advanced solid tumor patients (Tanaka and Sakaguchi 2017). Agonistic antibodies specific for 
other TNFR super family molecules, such as OX40, are under clinical investigation too 
(Nishikawa and Sakaguchi 2014). 
• Small molecules for Treg depletion or functional modulation. One example of small molecule 
targeting Treg cells is cyclophosphamide, an anti-neoplastic used frequently in traditional 
chemotherapy. It is an alkylating agent that interferes with DNA replication and it kills highly 
proliferating cells, and thus all T cells. However, when used at low doses over a long term, the 
drug has been shown to selectively reduce proliferating Treg cells including those in the tumor 
tissues, and enhance anti-tumor immune responses in humans and rodents (Motoyoshi et al. 
2006; Ge et al. 2012).  
Another potential strategy to augment tumor immunity via depleting Treg cells is to target 
TCR signaling molecules, which are differentially controlled in Treg and Tconv cells. ZAP-70 
(tyrosine kinase ζ-associated protein of 70 kDa), is a cytoplasmic protein tyrosine kinase, 
mainly expressed in T cells, that plays a critical role in the events involved in initiating T-cell 
responses by the antigen receptor. It is specifically repressed in Treg cells upon TCR activation 
(Ohkura et al. 2012). Targeting ZAP-70 could be responsible of selective reduction of TCR 
signaling, resulting in selective death of Treg cells, in particular effector Treg cells, due to 
signal deprivation-induced apoptosis (Tanaka and Sakaguchi 2017). Although these findings 
need to be confirmed in humans, the possibility to use TCR signaling molecules as therapeutic 
targets for selective depleting tumor infiltrating Treg cells is becoming a promising issue. 
To date, almost all studies about tumor associated Tregs have examined these cells as an 
homogenous population, with little, if any, characterization of Tregs heterogeneity. Thus, only 
an in-depth understanding of the functional features of tumor infiltrating Treg cell populations 
may lead to a comprehension of their role in tumor control and allow the identification of 
novel potential therapeutic targets for the effective modulation of these cells in cancer patients.  
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6. Treg cell plasticity: the role of long non coding RNAs 
Treg cell identity is truly important for immune homeostasis (Ohkura, Kitagawa, and 
Sakaguchi 2013) and understanding the precise nature of Treg cell stability is crucial for 
therapeutic applications that use or modulate Treg cells to treat autoimmune diseases, allergies, 
graft rejection and tumors (Sakaguchi et al. 2013). Whether Treg cells are phenotypically and 
functionally stable is a controversial issue. To resolve this apparent controversy about the 
plasticity of Treg cells, a few models have been proposed. The first concerns the 
“heterogeneity model” proposed by Hori et al., in which Treg cells consist of heterogeneous 
populations with different degrees of commitment, including fully committed Treg cells that 
are stable and less committed Treg cells, unstable (Hori 2014). Another model is the “transient 
flexibility model” proposed by Piccirillo and coworkers, in which Treg cells are flexible in 
terms of their phenotype depending on the environment in which they are in (Bin Dhuban et al. 
2014).  
In this context, lncRNAs have a fundamental role in governing flexibility and plasticity or cell 
identity maintenance, together with lineage specific transcription factors. In particular, what is 
emerging from literature is that ncRNAs typically act as fine-tuners of fate choices and this 
seems to be true not only in the immune system. Nonetheless, in the case of CD4+ T cell 
subsets that are specified but not fully determined, subtle changes in extrinsic signals can 
reverberate through responsive ncRNAs inducing changes that alter cell phenotype (Pagani et 
al. 2013).  
Usually the stability of lineage identity is achieved through the implementation and inheritance 
of epigenetic modification and lncRNAs can act directly on histone and DNA modifiers 
redefining this context. This condition allows them to be more flexible and sensitive to 
variations without disrupting the whole network integrity (Zhang et al. 2012). Several single-
case or genome-wide studies on lncRNAs in the murine immune system are now available in 
literature, whereas only few studies have been conducted until now in the human context and 
their cumulative impact on immune functions remains largely unknown (Satpathy and Chang 
2015). 
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6.1	Long	non	coding	RNAs	classification		
The non coding RNAs are classified based on their size into small and long non coding 
(table1). Some of these ncRNAs have general housekeeping functions and include ribosome- 
associated RNA (rRNA), transfer RNA (tRNA) and small/nuclear RNA (sn/snoRNA). 
Different classes of short RNAs (miRNA, siRNA, piRNA) exhibit regulatory functions in 
various cellular processes, including cell identity (Ciaudo et al. 2009), cancer progression 
(Garg 2012) and immunity (Ha 2011). Long noncoding RNAs (lncRNAs) represent a large 
portion of noncoding regions across the genome (Derrien et al. 2012) and constitute a set of 
functional transcripts over 200 nucleotides on length with no potential to encode for functional 
proteins of more than 30 aminoacids (Li X et al., 2013).  
 
Table 1 - Main classes and functions of mammalian ncRNAs. 
 
LncRNAs are commonly classified in association with annotated protein-coding mRNA and 
comprise the long intergenic ncRNAs (lincRNA), intronic lncRNA, sense or antisense 
lncRNA, competitive endogenous RNAs (ceRNA) and enhancer RNA (eRNA). The more 
abundant category of ncRNAa are sense ncRNAa that overlap coding mRNA on the same 
strand and share some sequence to the latter, yet do not encode proteins (Kapranov et al. 2005). 
This class includes unspliced sense intronic RNAs (PINs) and spliced transcripts that combine 
exons from coding and non coding region of a gene (Djebali et al. 2012). The intronic 
lncRNAs emerge from the intron of a protein coding gene and these transcripts compose the 
majority (around 70%) of all non coding nuclear-encoded RNA. Some of these transcripts 
include circular ncRNAs (ciRNA) that are involved in the regulation of the expression of their 
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parent genes (Zhang et al. 2013). Another class of lncRNAs comprises antisense transcripts 
that overlap the opposite DNA strand of the associated protein coding genes (Medical 2005). 
Intergenic long ncRNAs are the most studied lncRNAs because they are independent 
transcriptional units and are more likely associated with an intrinsic function that being 
transcriptional noise (Fig. 7).  
LncRNAs are also classified according to their localization in the cell compartments: nuclear 
lncRNAs and cytoplasm lncRNAs. Nuclear lncRNAs have been found to be mainly implicated 
in the recruitment of chromatin modifiers in specific genomic loci ( John L. Rinn 2013) and 
they can work as transcriptional activators through the recruitment of chromatin-modifying 
complexes and determine changes in three-dimensional chromatin conformation mediated by 
the activation of specific enhancer regions (Wang et al. 2011).  It’s possible to distinguish 
nuclear lncRNAs by their course of action: cis and trans-acting RNAs. The first one is 
involved in the control of the expression of genes located in the proximity of their transcription 
sites and sometimes can spread their action to long distance on the same chromosome (Fatica 
and Bozzoni 2014); the latters can both activate or repress the expression of genes located in 
independent loci (Guttman et al., 2009).  
Cytoplasmatic lncRNAs mediated gene regulation mechanism: they can modulate the control 
of translation by base pairing recognition of the target and mRNA stability (Faghihi et al. 
2010).  
 
Figure 7 LncRNAs (orange) classification respect to neighbouring coding regions (green). 
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6.2	Involvement	of	lncRNAs	in	immune	response	
The development and activation of immune cells depend on the strictly integrated and dynamic 
gene expression mechanisms that are regulated by a series of transcriptional and post-
transcriptional events. If the roles of coding genes, in the regulation of gene expression in the 
immune system have been elucidated, the regulatory roles of non-coding RNAs are still 
understood. So far, a large number of studies demonstrated the connection between lncRNAs 
and immune regulation such as immune responses and infectious diseases. The first evidence 
suggesting the potential role of lncRNAs in regulation of immune system comes from Guttman 
and colleagues reporting that CD11C+ bone-marrow-derived dendritic cells increase the 
expression of about 20 lincRNAs after being challenged by lipopolysaccharide (LPS), a 
specific agonist of the Toll-like receptor 4 (Guttman et al. 2009). 
Some lncRNAs are dynamically expressed during T cell development, differentiation and 
activation in the adaptive immune responses.  In mammalian CD8+ T cells, 1000 lncRNAs 
were identified and characterized, many of which displayed stage- or tissue-specific 
expression, neighbored protein-coding genes with well-characterized roles in CD8+ T cells, 
and/or overlapped shorter functional RNAs (Pang et al. 2009). 
Our group has generated a comprehensive atlas of transcriptome data from highly purified 
human lymphocyte subsets. This includes RNA-seq data for 13 human primary T and B 
lymphocyte subpopulations from peripheral blood of healthy donors, including CD4+naïve, 
Treg, T helper 1 (Th1), Th2, Th17, CD8+ naïve, central memory (TCM), effector memory 
(TEM), naïve B, memory B, and CD5+ B cells (Ranzani et al. 2015). Using de novo 
transcription reconstruction strategies, we have further discovered novel and previously 
unannotated noncoding transcripts, including intergenic non-coding RNAs (lincRNAs). 
Remarkably, analysis of lymphocyte cell-subset specificity revealed that lincRNAs display a 
more cell-specific expression pattern than coding genes (Fig. 8). 
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Figure 8: Unsupervised K-means clustering and specificity of lincRNAs (left) and coding genes (right) 
across 13 human lymphocyte subsets. Color intensity (key) indicates z-score log2-normalized raw FPKM 
counts. 
 
 
One of the major advances of our studies was to identify previously un-annotated lincRNAs 
and to determine their lymphocyte cell-subset specificity. Interestingly, what emerged is the 
discovery of lincRNAs located within the ICOS- CTLA4-CD28 genomic region. lincRNAs 
were shown to be expressed very poorly not only in non-lymphoid but also in lymphoid 
tissues, suggesting that they are likely to exert a highly specific role in lymphocyte function.  
These findings and the high cell specificity of lincRNAs suggest to consider lincRNAs as 
novel and highly specific molecular targets for the development of new therapies for diseases, 
such as autoimmunity, allergy and cancer in which altered CD4+ T cell functions play a 
pathogenic role. 
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AIM OF THE PROJECT  
One of the most peculiar features of CD4+ Treg cells consists on the phenotypic plasticity that 
they display adapting to different environment. Treg cells can accumulate in tumor tissues 
where they are generally associated with worsened prognosis. The molecular mechanisms, 
though, underlying Treg cell functional and phenotypic variation as well as their clinical 
significance at tumor sites are still largely unknown. For this reason, only a deep investigation 
of the molecular networks defining tumor infiltrating Treg cell populations may lead to a better 
comprehension of their role in tumor immune escape. 
To achieve this goal we performed whole transcriptome analysis from Treg cells isolated from 
both healthy donors and from colorectal and non-small cell lung cancer patients, to identify the 
unique molecular features of Treg cells assessing the expression of both coding and non-
coding transcripts that best define the identity of these cells and might therefore represent 
novel prognostic markers or therapeutic targets for functional modulation of these cells at 
tumor sites. 
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MATERIALS AND METHODS 
Purification and colture of human lymphocytes subsets  
Buffy-coated blood of healthy donors was obtained from the I.R.C.C.S. Istituto di Ricovero e 
Cura a Carattere Scientifico Policlinico Cà Granda in Milan and peripheral blood mononuclear 
cells were isolated by Ficoll-Hypaque density gradient centrifugation. All healthy donors were 
subjects with no history of autoimmune diseases ad malignant tumors. Lymphocyte subsets 
were purified >95% by sorting on a FACSAria (BD) by various combinations of surface 
markers: OP-CD4 (Miltenyi); FITC-CD25 (Miltenyi); PE-CD127 (Miltenyi); APC-CD45RO 
(Miltenyi); PECy5-CD62L (Miltenyi). 
Isolated CD4+CD25 highCD127low Treg cells and CD4+CD25 lowCD127high naïve Tcells were 
expanded in vitro according to Rapid Expansion Protocol in presence of RPMI 1600 medium, 
10% fetal bovine serum (FBS), 100 unit/ml penicillin, IL-2 20 U/ml (Miltenyi), anti-human 
CD3 30 ng/ml (OKT3 clone, Biolegend), irradiated PMBC Feeders and Ebstein-Barr Virus 
immortalized B cell line (Rosi-EBV) (Dudley et al. 2003). 
 
ShRNA oligonucleotides designing and cloning 
Four shRNAs for each transcript were designed by using the GPP Web Portal 
(https://portals.broadinstitute.org/gpp/public/seq/search), an algorithm that ranks potential 
21mer targets within each human and mouse Refseq transcript. Those “candidates” targeting 
transcripts at different position with the higher intrinsic score (a number from 0 to 15 
predicting the knockdown successfulness) were selected (Table 1). 
ShRNAs as well as shRNA-non targeting control, were cloned into pLKO.1 Vector.  
Oligos containing a sense and an antisense sequence targeting mRNA, were annealed in 
presence of NEB Buffer2 New England Biolabs Restriction Endonuclease Reaction Buffer 
(50mMNaCl, 10mMTris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.9@25°C). Once annealed, the 
dsDNA molecule obtained had at the 5’ a sticky end compatible with an AgeI digested site, 
while at the 3’ the end was suitable for ligation with an EcoRI-digested site. The sense and 
antisense sequences are connected by a spacer capable of forming a loop. The digested 
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fragments were purificated with Wizard® SV Gel and PCR Clean-Up System and ligated into 
pLKO.1 cloning vector by using T4 DNA ligase (Promega) and the ligation products was then 
transformed into competent STBL3 bacteria, following manufacturer’s protocol and then 
plated on LB agar containing 100 ug/ml ampicillin.  
Plasmids successfully ligated by restriction enzime digestion, were selected by sequencing and 
DNA plasmid was isolated using PureLink™ HiPure Plasmid Midiprep Kit 
(Invitrogen). 
 
 
Table1: shRNA design. 
Lentiviral production and Titration 
Twenty four hours prior to transfection, HEK293T were plated at 60% confluence in presence 
of Dulbecco’s modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 100 unit/ml penicillin, 100unit/ml glutamine and incubated at 37°C with 5% CO2.  
During transfection, 25 ug of shRNA-lentivirus-GFP were transfected with 16ug of viral 
packaging pS-PAX2 and 8.4ug viral envelope pMD2.G into HEK293T according to Clacium 
Phospate method. Twelve to sixteen hours after transfection, the medium was aspirated and 
replaced with 16 ml of pre-warmed fresh medium to the plate. Cell culture supernatant was 
collected 42 hours after transfection and ultra-centrifuged at 20000 rpm at 4°C for 2h 
(Beckman Coulter).  
The viral particles were resuspended in RPMI medium and stored at -80°C. Concentrated viral 
particles were titrated at different dilutions and transduced into HEK 293T cells. The 
percentage of GFP positive cells was assessed two days after transduction by using FACS 
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CANTO FlowCytometer (BD). 
Lentiviral transduction 
Seven days post rapid expansion protocol, 300000 expanded in vitro Treg cells were 
transduced with either control lentiviral vector (LVV MOCK GFP) or ShRNA- lentiviral 
vectors (LVV shRNA GFP) at a multiplicity of infection of 1x108 transducing units per ml in 
the presence of IL-2 20 U/ml (Miltenyi). At 7th day post transduction, GFP positive cells were 
isolated by using a FACS Aria Flow Cytometer (BD), then they were used for RNA extraction 
as well as for suppression assay.  
RNA isolation and RT-qPCR Analysis 
Total RNA was isolated using mirVana Isolation Kit (Invitrogen) according to suggested 
protocol. Briefly, the lysates were extracted with Acid-Phenol Chloroform and further purified 
to yield total RNA. Extracted RNA was quantified with QuantiFluor RNA System (Promega) 
and then quality controlled for integrity with 2100 Bioanalyzer (Agilent Technologies).  For 
reverse transcription, equal amounts of DNA-free RNA (70 ng) were reverse-transcribed with 
SuperScript III (LifeTechnologies) following the standard protocol. Diluted cDNA (3,5 ng) 
was then used for RT-qPCR to assess the following transcripts: ncRNA_up_1 (AR2W7P7), 
ncRNA_up_2 (AR47W2), 18s (Hs0392985_g1), B2M (Hs00174383_g1), and CTLA4 
(Hs00175480_m1) gene expression levels with Inventoried TaqMan.  
qPCR BioMark™ 
The time course analysis was performed exploiting the BioMark™ technology and using the 
96x96 quantitative PCR (qPCR) DynamicArray microfluidic chips (Fluidigm). A 2.25 μl 
aliquot of amplified cDNA was mixed with 2.5 μl of TaqMan Fast Advanced Master Mix 
(Thermo Fisher) and 0.25μl of Fluidigm’s “sample loading agent,” then inserted into one of the 
chip “sample” inlets. A 2.5 μ l aliquot of each 20X TaqMan assay was mixed with 2.5 μl of 
Fluidigm’s “assay loading agent” and individually inserted into one of the chip “assay” inlets. 
Samples and probes were loaded into 96 x96 chips using an IFC Controller HX (Fluidigm), 
then transferred to a BioMark real-time PCR reader (Fluidigm) following manufacturer’s 
instructions.  
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Suppression assay 
CFSE-labeled responders CD4+Naive+T cells from healthy donors were induced to proliferate 
in the presence of anti-CD3/CD28 dynabeads (Gibco) (1 bead : 20 cells) and co-cultured at 
different ratios (Naïve: Treg 1:1, 1: 0,5, 1:0,25) with unlabeled GFP+ transduced Treg cells 
from peripheral blood of healthy donors, using FACS Aria II (BD Biosciences). 
Proliferation of CFSE-labeled cells was assessed after 96 hours, using FACS Canto flow 
cytometer (BD). 
Fractionation 
Cell fractionation was performed following the protocol published by Gagnon et al., (Gagnon 
et al. 2014).  
For RNA analysis, 2*106 expanded in vitro Treg cells were harvested at 500 g for 5 minutes at 
4°C, resuspended in ice-cold HLB supplemented with 100U of SUPERase-In and leaved on ice 
for 10 minutes. The samples were centrifuged at 1000 g for 3 minutes at 4°C and then, the 
supernatant, the cytoplasmatic fraction, was resuspended in TRIzol Reagent® (Life 
Technologies) and stored at -20°C. The pellet representing the semipure nuclei was washed 3 
times with ice-cold HLB and centrifuged at 200 g for 2 minutes at 4°C. The pellet was then 
further fractionated into nucleoplasmic and chromatin-associated RNA fractions by adding 
MWS buffer (10mM TrisHCl pH 7, 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40) 
supplemented with 100 units of SUPERase-in and leaved on ice for 5 minutes. Samples were 
centrifuged at 1000 g centrifugation for 3 minutes at 4°C, then the resulting supernatant 
rapresenting nucleoplasmic fraction was resuspended in TRIzol Reagent®. The resulting pellet 
constitutes the chromatin fraction and was washed 3 times in ice cold MWS, centrifuged at 500 
g for 2 minutes at 4 °C and finally resuspended TRIzol Reagent®. 
Chip 
At 14th day of Rapid Expansion Protocol, 107 in vitro expanded Treg cells from healthy donors 
were crosslinked in their medium with 1/10 of fresh formaldehyde solution (50 mM Hepes- 
KOH pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 11%formaldehyde) for 12 
minutes. Then they were treated with 1/10 of 1.25 M glycine for 5 minutes and centrifuged at 
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1350 g for 5 minutes at 4°C. Cell membranes were lysated in LB1 (50 mM Hepes-KOH 
pH7.5, 10 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton X-100 
supplemented with Protease Inhibitor Cocktail Tablets cOmplete, EDTA-free (Roche) and 
Phenylmethanesulfonyl fluoride (Sigma) at 4°C.  
Nuclei were pelletted at 1350 g for 5 minutes at 4°C and washed in LB2 (10 mM Tris-HCl pH 
8.0, 200 mM NaCl, 1mM EDTA, 0.5 mM EGTA) supplemented with protease inhibitors.  
Nuclei were again pelleted at 1350 g for 5 minutes at 4°C and resuspended with a syringe in 
200ul LB3 (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-
deoxycholate, 0.5% Nlauroylscarcosine) supplemented with protease inhibitors.  
Chromatin was fragmented by ultrasound and cell debris were pelleted at 20000 g for 10 
minutes at 4°C. Chromatin Immunoprecipitation was set up in LB3 supplemented with 1% 
Triton X-100, protease inhibitors and antibodies against H3K3Me1(Abcam), H3K4me3 
(Abcam), H3K27me3 (Millipore), or no antibody (as negative control) o/n at 4°C. The day 
after Dynabeads® Protein G (Novex®) were added at left at 4°C rocking for 2 hours. Then the 
beads were washed twice with Low salt wash buffer (0.1% SDS, 2 mM EDTA, 1% Triton X-
100, 20 mM Tris-HCl pH 8.0, 150 mM NaCl) and with High salt wash buffer (0.1% SDS, 2 
mM EDTA, 1% Triton X-100, 20 mM Tris-HCl pH 8.0, 500 mM NaCl). Histones IPs were 
also washed with a LiCl solution (250 mM LiCl, 1% NP-40, 1 mM EDTA, 10 mM Tris-HCl 
pH 8.0). All samples were finally washed with 50 mM NaCl in 1X TE. Elution was performed 
o/n at 65°C in 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS. Samples were treated with 
0.02 ug/ul RNase A (Sigma) for 2 hours at 37 °C and with 0.04 ug/ul proteinase K (Sigma) for 
2 hours at 55°C. DNA was purified with phenol/chloroform extraction and quantified with 
QuantiFluor dsDNA System (Promega). qPCR was performed on diluted cDNA with 
PowerSyberGreen (LifeTechnologies) and specificity of the amplified products was monitored 
by performing melting curves at the end of each amplification reaction. ChIp quality was 
assessed by using primers designed on control genes (Table 2).  
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Table 2. Primers designed on control genes. 
ChIP-seq analysis was perfomed by bioinformatic team in our institute.  
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RESULTS 
Molecular characterization of Treg cells was pursued by performing whole transcriptome 
analysis of tumor infiltrating Treg cells (results presented in Part I) and of cells isolated from 
the peripheral blood of healthy donors (results presented in Part II). Through the comparison of 
Treg cell transcriptome data with datasets of thirteen distinct human lymphocyte subsets we 
defined the profile of Treg specific coding and non-coding transcripts and then pursue the 
functional characterization of non-coding RNAs identified in proximity of CTLA4 gene whose 
prominent role in Treg cell biology is well established. 
PART I 
1. Tumor infiltrating Tregs cells upregulate immune checkpoints 
and are highly suppressive 
Treg cells share with effector lymphocytes most of the molecules targeted for therapy, which 
can possible deplete also the tumor specific effector cells. Therefore, the molecular 
characterization of Treg cells at different tumor sites and the comparison with effector subsets 
should help to better define their signature molecules and of the network that regulates Treg 
cell functions in the tumor microenvironment. 
To assess the gene expression landscape of tumor infiltrating CD4+ T cells, we isolated 
different CD4+ lymphocytes subsets from two different tumors, NSCLC and CRC, from the 
adjacent normal tissues, and from peripheral blood samples. From all these tissues, we purified 
by flow cytometry (Fig. 1) CD4+ Treg (36 samples from 18 individuals), Th1 (30 samples from 
21 individuals) and Th17 (22 samples from 14 individuals) cells (Table 1).  
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Table 1: Purification and RNA-Sequencing of Human Primary Lymphocyte Subsets. For each cell subsets 
profiled by RNA-sequencing tissue of origin, surface marker combinations used for sorting, number of profiled 
samples, as well as number of mapped sequencing reads are indicated. M, million; CRC, colorectal cancer; 
NSCLC, non-small cell lung cancer; PB, peripheral blood. 
 
 
 
Figure 1: Purification and isolation of tumor infiltrating lymphocytes. Representation of sorting strategy of 
Treg cells infiltrating Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and their respective 
normal tissues. 
 
To assess Treg cell function we tested their suppressor activity and showed that Treg cells 
infiltrating either type of tumor tissues have a remarkably stronger suppressive activity in vitro 
compared to Treg cells isolated from the adjacent normal tissue and peripheral blood of the 
same patients (Fig. 2).  
A 
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Figure 2: Suppression activity of tumor infiltrating Treg cells and their respective healty tissues and 
peripheral blood. Representative flow cytometry plots showing suppressive activity of Treg cells isolated from 
tumor (NSCLC or CRC), normal tissue and blood of the same patient. 4 × 105 carboxyfluorescein diacetate 
succinimidyl ester (CFSE)-labeled CD4+ naive T cells from healthy donors were co-cultured with an equal 
number of Treg cells for 4 days with a CD3-specific mAb and CD1c+CD11c+ dendritic cells. Percentage of 
proliferating cells is indicated. Data are representative of three independent experiments. 
 
The polyadenylated RNA fraction extracted from the sorted CD4+ Treg, Th1 and Th17 cells 
was then analyzed by paired-end RNA sequencing obtaining about 4 billion of mapped ‘reads’ 
(Table1). First, we interrogated RNA-sequencing data of CD4+ T cells infiltrating both CRC 
and NSCLC and their matched normal tissues, to quantitate mRNA expression of known 
immune checkpoints and their ligands. Second, we analyzed RNA-seq data of CRC and 
NSCLC, as well as of normal colon and lung sample. We found that several immune 
checkpoints and their ligands transcripts were strikingly upregulated in tumor infiltrating Treg 
cells compared to both normal tissue and peripheral blood-derived Treg cells as well as to T 
and B lymphocyte subsets purified from peripheral blood mononuclear cells (PBMCs) (Fig. 
3A and 3B). 
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Figure 3: Transcriptome analysis of Tumor infiltrating Lymphocytes.  
A) Z-score normalized RNA-seq expression values of immune checkpoints genes are represented as a heatmap. 
Cell populations are reported as a color code in the upper part of the graph, while gene names have been assigned 
to heatmap rows. Hierarchical clustering results are shown as a dendrogram drawn on the left side of the matrix. 
Colon tissues are indicated as C, lung tissues as L, and peripheral blood as B. 
B) RNA-seq normalized counts data for selected immune checkpoints and their ligands are shown as histogram 
plot. Cell population names are reported in the lower part of each graph, while gene names are shown in the upper 
part. To distinguish the origin of the different populations a color code has been assigned (upper right part of the 
figure). 
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Our findings highlight the specific expression patterns of immune checkpoints and their 
ligands in tumor infiltrating Treg and effector cells and suggest that their functional relevance 
should be investigated directly at tumor sites. 
 
2. Tumor-infiltrating Treg cells express a specific gene signature 
We then asked whether tumor infiltrating Treg cells could be defined by specific gene 
expression patterns. Firstly, in order to capture the overall similarity between the tumor 
infiltrating lymphocytes we performed a Principal Components Analysis (PCA) on the whole 
transcriptomes. Tumor infiltrating Treg cells purified from CRC and NSCLC tissues clustered 
together, and were clearly separated from Th1 and Th17 cells purified from CRC and NSCLC 
tissues (Fig. 4A). PCA showed a distinct grouping of Treg cells purified from different sites; in 
fact, separation along the first principal component (PC1) clearly divided peripheral blood 
Treg cells from tissue infiltrating Treg cells (Figure 4B), whereas normal-tissue and tumor-
tissue infiltrating Treg cells are mostly divided by the second component (PC2). These 
findings indicate that tumor-infiltrating Treg cells have specific expression patterns compared 
not only to other CD4+ T cell subsets but also compared to Treg cells isolated from normal 
tissues. 
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Figure 4: Principal Components Analysis (PCA) on the whole transcriptomes. 
A) Principal Component Analysis (PCA) has been performed on rlog-normalized (DESeq2) counts for tumor 
infiltrating CD4+ Treg, Th1 and Th17 cells RNA-seq data in CRC and NSCLC samples. B) PCA has been 
performed on rlog-normalized counts for all T regulatory cell RNA-seq samples (36 samples from 18 
individuals). 
 
 
To identify signature transcripts of tumor-infiltrating Treg cells, we included in the expression 
pattern analyses the transcriptome dataset previously obtained from different T and B 
lymphocyte subsets purified from PBMCs (Ranzani et al., 2015). In so doing, we obtained a 
signature of 309 transcripts whose expression is higher in tumor infiltrating Treg cells 
compared to the other lymphocyte subsets purified from non-tumoral tissues and from PBMCs 
of healthy or neoplastic patients (Fig. 5). 
A 
B 
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Figure 5: Tumor-infiltrating Treg cells express a specific gene signature. Z-score normalized expression 
values of genes that are preferentially expressed in tumor-infiltrating Treg cells (Wilcoxon Mann Whitney test p < 
2.2 × 10–16) over the listed cell subsets are represented as boxed plots. Colon tissues are indicated as C, lung 
tissues as L, and peripheral blood as B. 
 
 
Altogether, the data show that Treg cells display the most pronounced differences in transcripts 
expression among CD4+ T cell subsets infiltrating normal and tumor tissues. We defined a 
subset of signature genes that describe the specific gene expression profile of tumor infiltrating 
Treg cells. 	
3. Tumor infiltrating Treg signatures genes are upregulated in 
other tumors  
The overlap between the signature genes in the CRC and NSCLC infiltrating Treg cells (Fig. 
5) prompted us to assess whether this signature were also enriched in Treg cells infiltrating 
other tumors. RNA was thus extracted from Treg cells infiltrating breast cancer, gastric cancer, 
brain metastasis of NSCLC, and liver metastasis of CRC. We found by RT-qPCR that tumor 
infiltrating Treg signatures genes were mostly upregulated also in these tumors (Fig. 6).  
			 45	
Overall these data show that the tumor-infiltrating Treg 
cell signature genes are co-expressed at single cell level 
with FOXP3 and IL2RA and that several primary and 
metastatic human tumors express the tumor-infiltrating 
Treg cell signature. 
 
 
Figure 6: Gene-expression analysis of tumor Treg signature 
genes in different tumor types. Expression values are expressed 
as log2 (2^-DCt). 
 
4. Gene signature of tumor infiltrating 
Treg cells is translated in  protein 
signature 
We then assessed at the single cell level by flow 
cytometry the protein expression of ten representative 
signature genes present in CRC and NSCLC infiltrating 
Treg cells, adjacent normal tissues, and patients 
PBMCs. Of the ten proteins, two were proteins (OX40 
and TIGIT) whose relevance for Treg cells biology has 
been demonstrated (Joller et al., 2014; Voo et al., 2013), 
seven are proteins (BATF, CCR8, CD30, IL-1R2, IL-
21R, PDL-1 and PDL-2) whose expression has never 
been described in tumor-infiltrating Treg cells, and one 
protein, 4-1BB, is a co-stimulatory receptor expressed 
on several hematopoietic cells, whose expression on 
Treg cells has been shown to mark antigen-activated 
cells (Schoenbrunn et al., 2012). Our findings showed 
that all these proteins were upregulated (Fig 7A), to different extent, in tumor infiltrating Treg 
cells compared to the Treg cells resident in normal tissues. Given the increasing interest in the 
PD1 - PDLs axis as targets for tumor immunotherapy, we assessed the effect of antibodies 
against PDL-1 and PDL-2 on the suppressive function of Tumor-infiltrating Treg cells toward 
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effector CD4+ T cell proliferation in vitro. We found that pre-incubation of tumor infiltrating 
Treg cells with monoclonal antibodies against PDL-1 or PDL-2 reduced their suppressive 
activity as demonstrated by the increased proliferation of effector CD4+ T cells (Fig 7B). 
 
 
 
Figure 7: Expression of Tumor-Infiltrating Treg Cells Protein Signatures in CRC and NSCLC Samples. 
A) Representative flow cytometry plots for tumor (purple line) normal (green area) tissue infiltrating Treg cells 
and peripheral blood Treg cells (blue line) analyzed for the expression of the indicated proteins. 
B) Flow cytometry plots representative of four independent experiments showing suppressive activity of CRC 
infiltrating Treg cells on proliferation (shown as CFSE dilution) of CD4+ effector T cells. First panel shows the 
A 
B 
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inhibitory effect of Treg cells on the effector T cell proliferation in the presence of an isotype control antibody. 
The other panels show the inhibitory effect of Treg cells that have been pre-incubated with anti PD-L1 or PD-L2 
antibodies. Percentage of proliferating cells is indicated. The calculated division index is 0.26 in the presence of 
the control antibody; 0.57 in the presence of anti-PDL-1 and 0.39 in the presence of anti-PDL-2. Data are 
representative of four independent experiments. 
 
Altogether, our data show there is a molecular signature of tumor infiltrating Treg cells, which 
can be detected both at the mRNA and at the protein levels. 
5. Expression of Tumor Treg signature genes is negatively 
correlated with patient survival 
In an attempt to correlate our findings with clinical outcome, we asked whether the expression 
of the tumor-Treg signature transcripts correlated with disease prognosis in CRC and NSCLC 
patients. We therefore interrogated for expression of Treg signature genes transcriptomic 
datasets obtained from resected tumor tissues of a cohort of 177 CRC patients (GSE17536 
(Smith et al., 2010) and of a cohort of 263 NSCLC patients (GSE41271 - (Sato et al., 2013), 
and correlated high and low gene expression with the 5-years survival data. Among those 
genes whose expression is highly enriched in tumor infiltrating Treg cells, we selected LAYN, 
MAGEH1 and CCR8 that are the three genes more selectively expressed (Fig. 8A).   
To normalize for differences in T cell densities within the resected tumor tissues, we used the 
ratio between expression of the selected signature genes and CD3G. We found that high 
expression of the three signature genes is in all cases correlated with a significantly reduced 
survival (Fig. 8B). We also observed that expressions of the three signature genes increased 
with tumor staging of CRC patients (Fig. 8C). 
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Figure 8: Prognostic Value of Signature Transcripts of Tumor Infiltrating Treg Cells. A) Kaplan-Meier 
survival curve comparing the high and low expression of the tumor Treg signature transcripts (CCR8, MAGEH1, 
LAYN) normalized to the CD3G for the CRC (n = 177) and NSCLC (n = 263) studies. Univariate analysis 
confirmed a significant difference in overall survival curve comparing patients with high and low expression. 
Statistical significance was determined by the log-rank test. (CRC: p = 0.05 for CCR8, p = 1.48 × 10−3 for 
MAGEH1, p = 2.1 × 10−4 for LAYN; NSCLC: p = 0.0125 for CCR8, p = 0.035 for MAGEH1, p = 0.0131 for 
LAYN.) Each table depicts the Kaplan-Meier estimates at the specified time points. B) Expression distributions of 
CCR8, MAGEH1, and LAYN according to tumor staging at the time of surgery in the cohort of CRC patients. 
	B 
	C 
A 
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In conclusion, high expression in the whole tumor samples of three genes (LAYN, MAGEH1 
and CCR8) that are specifically and highly expressed in tumor infiltrating Treg cells, correlates 
with a poor prognosis in both NSCLC and CRC patients.  
PART II 
6. Identification of putative Treg specific long-non coding RNA  
Besides unique coding genes that characterize Treg cells, we also investigated the expression 
and specificity of non-coding transcripts whose regulatory role is by now well established in 
many cellular contexts. To assess the landscape of long-non coding RNA in human immune 
cell subsets, we generated a comprehensive transcription analysis from 13 human primary T 
and B subpopulations from peripheral blood of healthy donors, including CD4+ naive, Treg, 
Thelper 1 (Th1), Th2, Th17, TCM, TEM, CD8+ naive, TCM, naive B, memory B, and CD5+ 
B cells  (Figure 9a) (Ranzani et al. 2015) 
To discover novel specific non-coding transcripts, we performed de novo transcriptome 
reconstruction, identifying 4021 previously not-annotated non coding transcripts, including 
long intergenic non coding RNAs (lincRNAs) (Ranzani et al. 2015). LincRNAs were identified 
by selecting transcripts longer than 200 nucleotides, multiexonic, and which did not overlap 
with protein coding genes. Furthermore we excluded transcripts that contain: 
• a conserved protein-coding region and transcripts with putative ORFs that contain protein 
domains catalogued in Pfam (protein family database) (Finn et al. 2014) 
•  a comparative genomics method that efficiently predict transcript coding potential exploiting 
PhyloCSL. 
Among all these novel non-coding RNAs, we found 4 different transcripts codified by 2 genes 
located in proximity of CTLA4 gene: INGMG_001499 in the upstream region of CTLA4 gene 
and INGMG_001500, downstream CTLA4 gene. Each of them is transcribed into two specific 
primary transcripts that give rise to two different isoforms for each: ncRNA_up_1 and 
ncRNA_up_2 for INGMG_001499, ncRNA_down_1 and ncRNA_down_2 regarding 
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INGMG_001500 (Fig 9b). Given the importance of CTLA4 in Treg cell biology we focused 
our attention on these specific transcripts and investigated their role in Treg cell biology.  
 
 
 
Figure 9: Identification of new Treg specific lincRNAs. A) Heatmap of normalized expression values of 
lymphocytes signature lincRNAs selected on the basis of fold change (>2.5 with respect to all the other subsets), 
intrapopulation consistency (expressed in at least 3 out of 5 samples) and non parametric Kruskal-Wallis test (P < 
0.05). B) Localization of ncRNA_up_1, ncRNA_up_2, ncRNA_down_1 and ncRNA_down_2 within CTLA4 
genomic region on chromosome 2q33.  
 
 
We then compared the expression levels of these non-coding transcripts in RNA-seq data of 
CRC infiltrating Treg cells as well as Treg cells isolated by peripheral blood of healthy donors. 
Interestingly, we found that the expression levels of these new non-coding transcripts were 
higher in tumor infiltrating Treg cells compared to healthy donors peripheral blood (Fig. 10). 
INGMG_00149
9	 INGMG_001500	 
5	Kb 
	 		 	ncRNA_up_1 ncRNA_up_2 ncRNA_down_1 ncRNA_down_2 CTLA4 	
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Figure 10: RNA-seq data in the CTLA4 genomic locus. The position of the novel Treg-specific lincRNAs in 
relation to the co-receptor gene is shown. Reads mapping CTLA4 locus regions in Treg isolated from healthy 
donor peripheral blood (Treg HD) as well as tumor infiltrating Treg cells (Treg TIL) are displayed.  
 
Moreover, gene expression analysis confirmed that INGMG_001499 and INGMG_001500 
gene expression is correlated with CTLA4 only in Treg cells isolated from peripheral blood 
compared to other cell subsets analyzed (Fig. 11) 
 
Figure 11: Gene expression analysis on INGMG_1499, INGM_1500 and CTLA4 among different cell 
subsets.  
 
The data obtained in silico were also confirmed in vitro through qRT-PCR performed on total 
RNA isolated from CD4+ naïve T cells and Treg cells of healthy donor’s peripheral blood 
(Fig.12). 
  
 
 
Figure 12: Relative expression 
levels of non coding transcripts 
in Treg and naive T cell. The 
qPCR was performed on three 
different biological replicates. 
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Finally, we investigated the gene expression changes of CTLA4 and these novel non coding 
RNAs under investigation in a time course analysis on expanded in vitro Treg cells with anti-
CD3-CD28 beads. In these conditions, we observed the transient expression of CTLA4 upon 
activation, that is not associated with the up-regulation of ncRNAs, which, in contrast, are 
characterized by stable expression pattern over the time. These results suggested that CTLA4, 
INGMG_001499 and INGMG_001500 genes are independent transcriptional units (Fig. 13).  
 
 
Figure 13: Relative expression levels of CTLA4 and ncRNAs transcripts. Treg cells were stimulated with 
anti-CD3/CD28 beads and mRNA was isolated after 12h, 24h, 72h, 7days and 14 days activation stimulus. 
Results are representative of three independent experiments. 
 
7. Treg specific long-non coding RNAs are chromatin bound  
Hints on the long non-coding RNA functions might derive from information on their 
subcellular localization. We therefore investigated the cellular compartmentalization of the 
identified non-coding transcripts by performing biochemical cell fractionation. Thereby, we 
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obtained three different fractions, including cytoplasm, nucleoplasm and chromatin. To 
evaluate the quality of the isolated sub-cellular fractions we tested subcellular enrichment of 
three known RNAs: RNU2.1 (RNA, U2 small nuclear 1) is RNA component of the U2 snRNP 
that interacts with 3’ region of the intron during splicing events and for this reason it is 
localized in the chromatin fraction; Malat1 is a long non coding RNA retained in the nucleus 
that is thought to form molecular scaffolds for ribonucleoprotein complexes and it may also act 
as a transcriptional regulator for numerous genes; Linc00339 is a long intergenic non coding 
RNA mainly localized in the cytoplasm, as shown in Fig. 17. Interestingly, both upstream and 
downstream CTLA4 non coding transcripts are mainly enriched in chromatin fraction (Fig. 
14). 
 
Figure 14: Biochemical fractionation of novel lncRNAs and controls. The results represent the average of 
three different experiments. 
 
 
8. Epigenetic analysis of Upstream and Downstream CTLA4 
regions 
Due to the prominent chromatin localization of these lncRNAs we performed a more detailed 
analysis of the epigenetic modifications to assess whether these genes are long non-coding 
RNA or enhancer RNAs. To address this issue, we characterized the epigenetic modifications 
upstream and downstream CTLA4 regions by chromatin immunoprecipitation seq (ChIP-seq). 
We profiled genomic occupancy of H3K4me3, associated with active promoters, H3K27me3 
that marks repressive chromatin, H3K27ac, associated with active promoters and enhancers 
nc
RN
A_
up
_1
nc
RN
A_
up
_2
nc
RN
A_
do
wn
_1
Inc
RN
A_
do
wn
_2
Lin
c0
03
39
Ma
lat
1
RN
U2
.1
0.0
0.5
1.0
1.5
Cytoplasm 
Nucleoplasm 
Chromatin 
R
el
at
iv
e 
to
 to
ta
l
		
		 54	
(Creyghton et al. 2010) and H3K4me1, related to regulatory regions including enhancers 
(Heintzman et al. 2007).  
We first tested the histone modifications enrichments of control genes: IL2RA (CD25), that 
should display epigenetic modification associated to active transcription and HOXD11 that we 
know to be switched off in Treg cells. As reported in Fig.15, we obtained expected results. 
 
 
Figure 15: Epigenomic tracks of control genes, IL2RA (CD25) and HOXD11. H3K4me3, H3K27Ac and 
H3K27me3 enrichments are displayed. The arrows reflect the transcriptional direction. 
 
 
We then generated genome-wide H3K4me3, H3K27Ac and H3K4me1 maps of the non-coding 
regions of our interest. As shown in Fig. 16, CTLA4 locus regions are defined by marks 
associated to active chromatin. H3K4me3 and H3K27Ac enrichments are preponderant both in 
upstream and dowstream regions of CTLA4 gene. Intriguingly, we observed a different 
H3K4Me1 enrichment between upstream and downstream CTLA4 regions. It is by now 
established that H3K4Me1hgh/H3K4Me3low correlates with active enhancers in various systems 
while H3K4Me1low/H3K4Me3high is associated with active promoters (Natoli and Andrau 
2012). While the upstream regions presented a low ratio between H3K4Me1 and H3K4Me, 
which define them as long non-coding RNAs, the downstream ones are characterized by a 
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stronger enrichment of H3K4Me1 compared to H3K4Me3, suggesting that they are indeed 
more similar to eRNAs (Fig. 16). 
 
 
Figure 16: Epigenetic tracks of CTLA4 locus. The position of the novel Treg-specific lincRNAs in relation to 
the co-receptor genes is shown. H3K4me3, H3K27Ac, H3K4me1 peaks for Treg isolated from peripheral blood 
of healthy donors are displayed. 
 
9. shRNAs downregulate at least 50% lincRNAs ncRNA_up_1 and 
ncRNA_up_2 
Since CTLA4 is one of the key transcript for Treg cell biology we wondered whether long 
non-coding RNA upstream of CTLA4 region might have a role in regulating Treg cell function 
as well. Indeed there are many examples in the literature of chromatin bound long non-coding 
RNAs that recruit activating or repressive histone modifiers on specific genomic region (Joh, 
RI, Palmieri, CM, Hill, IT, Motamedi 2015). 
Therefore, in order to study the putative effects of these long non-coding RNAs, we carried out 
knockdown experiments via shRNA to determine if their modulation could have an effect on 
the Treg suppressive function.  
We designed 5 shRNAs for each transcript and we assessed the knockdown efficiency, 
selecting shRNAs that decreased transcript levels by at least 50%. 
Expanded in vitro Treg cells were transduced with either control lentiviral vector (shRNA 
GFP) or lncRNA shRNA. At day 7 post transduction, GFP positive cells were isolated by 
FACS sorting, and downregulation effect was assessed by qRT-PCR. As shown in Fig. 17, 
compared to mock control, three different shRNAs downregulated efficiently ncRNA_up_1 
(shB 60%, shD 55%, shE 80%) as well as ncRNA_up_2 (shB 85%, shC 75%, shD 80%). We 
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therefore selected these shRNAs to further perform functional experiments and investigated 
their role in Treg cell suppressive activity.    
 
 
Figure 17:  Downregulation effects on ncRNAup_1 and ncRNAup_ 2. Relative mRNA expression of 
ncRNA_up_1 and ncRNA_up_2 normalized to mock control are reported. Two-tailed paired t-test was performed 
(ns – not significant; ** p<0.01; *** p<0.001). Results are representative of three different experiments. 
 
10. Suppressive activity of Treg is compromised by downregulating 
ncRNA_up_1 and ncRNA_up_2 
Treg cells are characterized by their ability to suppress proliferation of effector T cells, which 
can be assessed with in vitro co-culture experiments. To test the effect of ncRNA_up_1 and 
ncRNA_up_2 down regulation on Treg cells suppressive function, CFSE-labeled responder 
naïve cells were put in culture in the presence of different ratios to Treg cells (1:1; 1: 0,5; 1: 
0,25). We first showed that Treg transduced with scrambled shRNA control vector (MOCK) 
and untransduced Treg cells (UT), had a remarkably strong suppressive activity in vitro. Fig. 
23 shows that, at different ratios between Naïve and Treg cells, MOCK and UT Treg cells 
remarkably reduce Naïve proliferation, which goes to 7%-15% and 1-5% respectively (Fig.18) 
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Figure 18: Representative flow cytometry plots showing suppressive activity of Treg cells isolated from 
peripheral blood of healthy donors. 2 × 105 carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled 
CD4+ naive T cells from healthy donors were cocultured alone (Responder) or with different ratios of Treg cells 
(1:1-1:0,5 –1,025) for 4 days in presence of anti CD3/CD28 stimulus. Percentage of proliferating cells is 
indicated. Data are representative of three independent experiments. 
 
 
In contrast, Treg cells transduced with shRNA against ncRNA_up_1 and ncRNA_up_2 
displayed a significant reduction of suppressive activity. Fig. 19 and 20 show that, naive cells 
co-cultured in presence of Treg cells transduced with shRNAs against ncRNA_up_1 and 
ncRNA_up_2, respectively, exhibit a remarkably increase of proliferation compared to MOCK 
and UT samples. These findings suggest that modulation of non-coding RNAs upstream of 
CTLA4 gene impairs Treg cell function, even if the molecular mechanisms underlying such 
modulation remain to be identified. 
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Figure 19: Representative flow cytometry plots: 2 × 105 carboxyfluorescein diacetate succinimidyl ester 
(CFSE)-labeled CD4+ naive T cells (Responder) from healthy donors were cocultured alone or with different 
ratios of Treg cells transduced with three different shRNAs against ncRNA_up_1 transcript (sh B, sh D, sh E). 
They were put in culture for 4 days with anti CD3/CD28 beads. Percentage of proliferating cells is indicated. Data 
are representative of three independent experiments. 
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Figure 20: Representative flow cytometry plots: 2 × 105 carboxyfluorescein diacetate succinimidyl ester 
(CFSE)-labeled CD4+ naive T cells (Responder) from healthy donors were cocultured alone or with different 
ratios of Treg cells transduced with three different shRNAs against ncRNA_up_2 transcript (sh B, sh C, sh D). 
They were put in culture for 4 days with anti CD3/CD28 beads. Percentage of proliferating cells is indicated. Data 
are representative of three independent experiments. 
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11. Single Nucleotides Polymorphisms (SNPs) overlap with 
discovered lincRNAs 
Another aspect that is worthwhile investigating is the presence within the identified lincRNAs 
of disease-associated polymorphisms reported in genome-wide association studies (GWAS). 
 Single nucleotide polymorphism (SNPs) in the CTLA4 locus have been associated with 
several autoimmune diseases including rheumatoid arthritis, type 1 diabetes, autoimmune 
thyroiditis, and multiple sclerosis (Welter et al. 2014). Beside SNPs identified in coding 
regions there are several SNPs that lie in non-coding regions and whose relevance has been 
neglected so far. We have thus intersected the lincRNAs with CTLA4-CD28-ICOS 
polymorphisms identified from publicly available GWAS catalogues (Li et al. 2016), or from 
fine-mapping studies based on probabilistic identification of causal SNPs (PICS)(Farh et al. 
2015). Notably, lincRNAs exons from novel transcripts overlap with PICS as well as linkage 
disequilibrium (LD) blocks containing GWAS SNPs and their highly correlated proxy (r2 
>0.8). This is in accordance with increasing evidence that disease-associated variants can 
affect regulatory elements whilst leaving their target protein coding genes intact. (Farh et al. 
2015)(Hon et al. 2017). Figure 21 displays the novel lincRNAs within CTLA4 locus, the 
position of SNPs as well as the distribution of promoter and enhancer-associated histone marks 
(H3K4me3, H3K27Ac, H3K4me1) in peripheral blood Treg cells. 
Maybe the SNPs falling within these regions might affect lncRNAs function in turn be relevant 
for Treg cell biology, such as in suppressive activity.  
 
 
 
Figure 21: Genetic, transcriptional and epigenetic data in the CTLA4 genomic locus. The position of the 
novel Treg-specific lincRNAs in relation to the co-receptor gene is shown. Candidate causal SNPs are displayed 
along with H3K4me3, H3K27Ac, H3K4me1 peaks for Treg isolated from peripheral blood of healthy donors. 
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DISCUSSION AND FUTURE PERSPECTIVES 
Innate and adaptive immune responses can play a role in many aspects of tumor biology. On 
the one hand, effector T-lymphocytes can suppress tumor growth by destroying cancer cells or 
inhibiting their growth. On the other hand, they can influence tumor progression either by 
selecting for tumor cells that are more fit to survive or by contributing to inflammation that 
facilitates tumor growth (Dunn, Bruce, Ikeda, Old, & Schreiber, 2002). Tumor specific CD8+ 
cytotoxic T cells have been for a long time considered as the ultimate anti-cancer effector cells 
of the immune system, since they can directly kill target cancer cells. Recently, a more direct 
anti-tumor role of effector CD4+ T lymphocytes has been documented as “helper cells” for 
CD8+ T-cell responses: tumor specific CD8+ and CD4+ effector T cells traffic to the tumor 
site, where CD8+ mediated killing of tumor cells thanks to the augmented cytokines released 
by CD4+ Th1 and Th17. These effector cells can be inhibited by different cell types 
contributing to the immunosuppressive environment at the tumor site. Among these cells, 
tumor infiltrating CD4+ T regulatory cells represent the most controversial but at the same 
time the most fascinating cell population. Indeed, we decided to focus in particular on Treg 
cells because their role as inhibitors of antitumor immune response has been fully recognized: 
they allow tumors to escape from immune surveillance, thus impairing immunotherapy (Frey, 
2013; Perrone et al., 2008). Despite promising clinical trials directed to deplete Treg cells in 
tumor microenvironment, the prognostic significance of tumor infiltration by Treg cells 
remains a matter of debate: while high levels of intra-tumoral Treg cells have been associated 
with poor prognosis in most human tumors, including lung, breast and liver, (Wilke, Wu, 
Zhao, Wang, & Zou, 2010), Treg cells infiltration of colorectal and gastric cancers has been 
associated with favorable outcomes (Ladoire, Martin, & Ghiringhelli, 2011). It is possible that 
the discrepancy about the role of Treg cells in different types of cancer depends on the 
heterogeneity of this cell population. Besides the classical division in natural-Tregs generated 
in the thymus and in induced-Treg cells generated in the periphery, Treg cells have recently 
been found to respond to varying contextual cues exhibiting substantial versatility. Treg cells 
adapt their transcriptional program to the various cytokines to which they are exposed in the 
inflammatory milieu, so resulting in various “effector-Treg cell populations” with different 
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migratory properties and effector functions (Cretney et al., 2011). This functional diversity 
illustrates the importance of studying Treg cells contextually to appreciate the multifaceted 
role of tumor-infiltrating Treg cells may play. To date, almost all studies about tumor 
associated Treg cells have examined these cells as an homogenous population, with little, if 
any, characterization of Treg cells heterogeneity. 
It is the rationale of this thesis: only in-depth understanding of the functional features of tumor 
infiltrating Treg cell populations may lead to a comprehension of their role in tumor control 
and allow the identification of novel potential therapeutic targets for cancer treatment. We first 
demonstrated that CRC- and NSCLC- infiltrating T cells are different compared to peripheral 
blood and normal tissue infiltrating Treg cells, suggesting that the tumor microenvironment 
determines specific gene signature in Treg cells. Moreover, the number of genes highly 
expressed in tumor infiltrating cells was significantly higher in Treg than in Th17 and Th1 
cells, indicating that Treg cells are also a more plastic cell population than other T cell subsets, 
and their phenotype is influenced by tumor microenvironment they are exposed to. Among 
signature genes, we found also that immune checkpoints, such as GITR, OX40, TIGIT, LAG-3 
and TIM-3 as well as some of their ligands, such as OX40LG, Galectin-9, CD70, are 
upregulated in tumor infiltrating Treg cells, suggesting that they could be taken into account as 
new therapeutic targets in cancer. Moreover, there were a number of interesting and less 
expected genes who were validated at the protein level and most of them have never been 
characterized in Treg cells such as PD-L1 and PD-L2. We also reported that tumor-infiltrating 
Treg cells express high amounts of 4-1BB (CD137) a marker of TcR-mediated activation 
(Schoenbrunn et al., 2012) and have shown an highly suppressive function on effector T cell 
proliferation, suggesting that expression of the signature genes correlated with the enhanced 
suppressive ability and so contributed to the development of a strong immunosuppressive 
environment at tumor sites. 
Another issue we provided, concerns the relationship between increased number of Treg cells 
in the tumor and the worst clinical outcome. In fact, LAYN, MAGEH1 and CCR8, which 
represent three of the most enriched genes in tumor infiltrating Treg cells, are highly detected 
in whole tumor samples and their detection is correlated with a significant worsening of the 5 
years survival of both CRC and NSCLC patients. Since LAYN, MAGEH1 and CCR8 have 
never been characterized in Treg cells, it could be very interesting investigating more in detail 
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their functional roles in Treg cells in order to develop new therapeutic approaches for cancer 
treatment.  
So far, there are several therapeutic approaches based on the modulation of specific genes 
expressed in Treg cells within the tumor environment, such as CTLA4. Compelling evidences 
come from a study by Simpson et al. which described the mode of action of a monoclonal 
antibody specific for cytotoxic T lymphocyte– associated antigen 4 (CTLA-4) (Simpson et al., 
2013), Anti-CTLA-4 treatment, that has demonstrated significant antitumor activity in clinical 
trials for metastatic melanoma (Dixon et al. 2003), has been shown to enhance intratumoral 
effector T cells activity by selective depletion of Treg cells in the tumor microenvironment. 
CTLA4 is an inhibitory costimulatory molecule constitutively expressed in FoxP3+ Treg cells. 
In contrast to CD28 signaling that promotes T cell activation, CTLA-4 serves an 
immunoregulatory function, suppressing the T cell response.  
RNA-seq data analysis performed in our laboratory revealed the identification of novel long 
non coding RNA signature, specifically expressed in CD4+ T regulatory cells. In particular, we 
focused our attention on those located within CTLA4 locus and we found that these lincRNAs, 
in addition to being Treg cell specific, are correlated with CTLA4 gene expression. The 
chromatin localization of these lncRNAs suggests a possible role in the functional modulation 
of CTLA4, but also of CD28 and ICOS genes that are localized near CTLA4 locus and that are 
pivotal genes for Treg cell identity. Indeed we demonstrated that modulation of CTLA4 
lincRNAs expression impair suppressive function of Treg cells. Nonetheless the underlying 
molecular mechanisms remain to be characterized. These aspects will be investigated with 
experiments that assess whole transcriptome changes upon lincRNAs modulation. 
Given the chromatin localization of CTLA4 lincRNAs, it is possible to postulate a role for 
these transcripts in inducing changes in the chromatin organization of this region which could 
be investigated with chromatin conformation capture experiments.  
Finally, our study reveals that mutations and dysregulations of these lincRNAs are associated 
with the development and progression of various complex human diseases including 
rheumatoid arthritis, type 1 diabetes, autoimmune thyroiditis, and multiple sclerosis. These 
findings suggest that some of these genetic mutations located within lincRNA might be 
pathogenic if they compromise the functions of these molecules by changes in their folding 
pattern, secondary structure expression, and stability (Mirza, Kaur, Brorsson, & Pociot, 2014).  
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All these findings demonstrate that Treg cells phenotype and function is the result of a fine 
equilibrium between coding and non coding genes and the dysregulation of both these 
elements may contribute to the development of diseases (Fig.1). Understanding the 
mechanisms of function of both coding genes and non-coding transcripts in Treg cells will 
provide us with important leads for translational studies and will drive the identification of 
novel and more specific therapeutic targets for immune-related diseases. 
 
 
Figure 1: Schematic representation of physiologic and pathologic conditions due to the 
equilibrium/disequilibrium state between coding and non-coding elements.  
			 65	
	
		
		 66	
	
			 67	
	
		
		 68	
	
			 69	
	
		
		 70	
	
			 71	
	
		
		 72	
	
			 73	
	
		
		 74	
	
			 75	
	
		
		 76	
	
			 77	
	
		
		 78	
	
			 79	
BIBLIOGRAPHY   
Abdel-Gadir, Azza, Amir H. Massoud, and Talal A. Chatila. 2018. “Antigen-Specific Treg Cells in 
Immunological Tolerance: Implications for Allergic Diseases.” F1000Research 7(0):38. 
Anon. 2017. “Control of Regulatory T Cell Development by the Transcription Factor Foxp3 Author 
( s ): Shohei Hori , Takashi Nomura and Shimon Sakaguchi Published by : American 
Association for the Advancement of Science Stable URL : 
Http://Www.Jstor.Org/Stable/3833558.” 299(5609):1057–61. 
Baecher-Allan, C., J. A. Brown, G. J. Freeman, and D. A. Hafler. 2001. “CD4+CD25high 
Regulatory Cells in Human Peripheral Blood.” The Journal of Immunology 167(3):1245–53. 
Bates, Gaynor J. et al. 2006. “Quantification of Regulatory T Cells Enables the Identification of 
High-Risk Breast Cancer Patients and Those at Risk of Late Relapse.” Journal of Clinical 
Oncology 24(34):5373–80. 
Bayer, Allison L., Alberto Pugliese, and Thomas R. Malek. 2013. “The IL-2/IL-2R System: From 
Basic Science to Therapeutic Applications to Enhance Immune Regulation.” Immunologic 
Research 57(1–3):197–209. 
Bonilla, Francisco A. and Hans C. Oettgen. 2010. “Adaptive Immunity.” Journal of Allergy and 
Clinical Immunology 125(2 SUPPL. 2):S33–40. 
Bopp, Tobias et al. 2007. “Cyclic Adenosine Monophosphate Is a Key Component of Regulatory T 
Cell–Mediated Suppression.” The Journal of Experimental Medicine 204(6):1303–10. 
Burchill, Matthew A. et al. 2008. “Linked T Cell Receptor and Cytokine Signaling Govern the 
Development of the Regulatory T Cell Repertoire.” Immunity 28(1):112–21. 
Burnet, M. 1957. “Cancer; a Biological Approach. I. The Processes of Control.” British Medical 
Journal 1(5022):779–86. 
Callewaert, Bert et al. 2012. “NIH Public Access.” 32(4):445–55. 
Chen, Wanjun and Joanne E. Konkel. 2010. “TGF-Beta and ‘adaptive’ Foxp3(+) Regulatory T 
Cells.” Journal of Molecular Cell Biology 2(1):30–36. 
Ciaudo, Constance et al. 2009. “Highly Dynamic and Sex-Specific Expression of MicroRNAs 
during Early Es Cell Differentiation.” PLoS Genetics 5(8):19–23. 
Clemente, C. G. et al. 1996. “Prognostic Value of Tumor Infiltrating Lymphocytes in the Vertical 
		
		 80	
Growth Phase of Primary Cutaneous Melanoma.” Cancer 77:1303–10. 
Clinic, Mayo. 2002. “Tumor-Associated B7-H1 Promotes T-Cell Apoptosis : A Potential 
Mechanism of Immune Evasion.” (4):793–800. 
Colombo, Mario P. and Silvia Piconese. 2007. “Regulatory T-Cell Inhibition versus Depletion: The 
Right Choice in Cancer Immunotherapy.” Nature Reviews Cancer 7(11):880–87. 
Cretney, Erika et al. 2011. “The Transcription Factors Blimp-1 and IRF4 Jointly Control the 
Differentiation and Function of Effector Regulatory T Cells.” Nature Immunology 12(4):304–
12. 
Creyghton, M. P. et al. 2010. “Histone H3K27ac Separates Active from Poised Enhancers and 
Predicts Developmental State.” Proceedings of the National Academy of Sciences 
107(50):21931–36. 
Curiel, Tyler J. et al. 2004. “Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma 
Fosters Immune Privilege and Predicts Reduced Survival.” Nature Medicine 10(9):942–49. 
Derrien, Thomas et al. 2012. “The GENCODE v7 Catalog of Human Long Noncoding RNAs : 
Analysis of Their Gene Structure , Evolution , and Expression.” 1775–89. 
Bin Dhuban, Khalid, Mara Kornete, Edward S. Mason, and Ciriaco A. Piccirillo. 2014. “Functional 
Dynamics of Foxp3 + Regulatory T Cells in Mice and Humans.” Immunological Reviews 
259(1):140–58. 
Dieckmann, D., H. Plottner, S. Berchtold, T. Berger, and G. Schuler. 2001. “Ex Vivo Isolation and 
Characterization of CD4(+)CD25(+) T Cells with Regulatory Properties from Human Blood.” 
Journal of Experimental Medicine 193(11):1303–10. 
Dixon, Christopher M. et al. 2003. “New England Journal.” England Journal of Medicine 
349(25):2387–98. 
Djebali, Sarah, Carrie A. Davis, Angelika Merkel, and Thomas R. Gingeras. 2012. “Landscape of 
Transcription in Human Cells.” Nature 489(7414):101–8. 
Dudley, Mark E., John R. Wunderlich, Thomas E. Shelton, Jos Even, and Steven A. Rosenberg. 
2003. “Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer 
Therapy for Melanoma Patients.” Journal of Immunotherapy 26(4):332–42. 
Dunn, Gavin P., Allen T. Bruce, Hiroaki Ikeda, Lloyd J. Old, and Robert D. Schreiber. 2002. 
“Cancer Immunoediting: From Immunosurveillance to Tumor Escape.” Nature Immunology 
3(11):991–98. 
			 81	
Dunn, Gavin P., Lloyd J. Old, and Robert D. Schreiber. 2004. “The Immunobiology of Cancer 
Immunosurveillance and Immunoediting.” Immunity 21(2):137–48. 
Egen, Jackson G. and James P. Allison. 2002. “Cytotoxic T Lymphocyte Antigen-4 Accumulation 
in the Immunological Synapse Is Regulated by TCR Signal Strength.” Immunity 16(1):23–35. 
Elkord, Eyad, Smita Sharma, Deborah J. Burt, and Robert E. Hawkins. 2011. “Expanded 
Subpopulation of FoxP3+ T Regulatory Cells in Renal Cell Carcinoma Co-Express Helios, 
Indicating They Could Be Derived from Natural but Not Induced Tregs.” Clinical Immunology 
140(3):218–22. 
Facciabene, Andrea et al. 2011. “Tumour Hypoxia Promotes Tolerance and Angiogenesis via 
CCL28 and Tregcells.” Nature 475(7355):226–30. 
Faget, J. et al. 2011. “Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg 
Recruitment through CCL22 Production by Tumor Cells.” Cancer Research 71(19):6143–52. 
Faghihi, Mohammad Ali et al. 2010. “Expression.” 14(7):723–30. 
Farh, Kyle Kai How et al. 2015. “Genetic and Epigenetic Fine Mapping of Causal Autoimmune 
Disease Variants.” Nature 518(7539):337–43. 
Fatica, Alessandro and Irene Bozzoni. 2014. “Long Non-Coding RNAs: New Players in Cell 
Differentiation and Development.” Nature Reviews Genetics 15(1):7–21. 
Fife, Brian T. and Jeffrey A. Bluestone. 2008. “Control of Peripheral T-Cell Tolerance and 
Autoimmunity via the CTLA-4 and PD-1 Pathways.” Immunological Reviews 224(1):166–82. 
Finn, Robert D. et al. 2014. “Pfam: The Protein Families Database.” Nucleic Acids Research 
42(D1):211–22. 
Fontenot, Jason D., Jeffrey P. Rasmussen, Marc A. Gavin, and Alexander Y. Rudensky. 2005. “A 
Function for Interleukin 2 in Foxp3-Expressing Regulatory T Cells.” Nature Immunology 
6(11):1142–51. 
Freeman, By Gordon J. et al. 2000. “Engagement of the PD-1 Immunoinhibitory Receptor by a 
Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation.” 192(7). 
Frey, Alan B. 2013. “NIH Public Access.” 192–205. 
Gabrilovich, D. et al. 1998. “Vascular Endothelial Growth Factor Inhibits the Development of 
Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic 
Lineages in Vivo.” Blood 92(11):4150–66. 
Gagnon, Keith T., Liande Li, Bethany A. Janowski, and David R. Corey. 2014. “Analysis of 
		
		 82	
Nuclear RNA Interference in Human Cells by Subcellular Fractionation and Argonaute 
Loading.” Nature Protocols 9(9):2045–60. 
Garg, Minal. 2012. “MicroRNAs, Stem Cells and Cancer Stem Cells.” World Journal of Stem Cells 
4(7):62. 
Garin, M. I. et al. 2007. “Galectin-1: A Key Effector of Regulation Meditated by CD4+CD25+ T 
Cells.” Blood 109(5):2058–65. 
Gavin, Marc A. et al. 2006. “Single-Cell Analysis of Normal and FOXP3-Mutant Human T Cells: 
FOXP3 Expression without Regulatory T Cell Development.” Proceedings of the National 
Academy of Sciences of the United States of America 103(17):6659–64. 
Ge, Yingzi et al. 2012. “Metronomic Cyclophosphamide Treatment in Metastasized Breast Cancer 
Patients: Immunological Effects and Clinical Outcome.” Cancer Immunology, Immunotherapy 
61(3):353–62. 
Ghiringhelli, François et al. 2005. “Tumor Cells Convert Immature Myeloid Dendritic Cells into 
TGF-β–Secreting Cells Inducing CD4  +  CD25  +  Regulatory T Cell Proliferation.” The 
Journal of Experimental Medicine 202(7):919–29. 
Gobert, Michael et al. 2009. “Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively 
Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse 
Clinical Utcome.” Cancer Research 69(5):2000–2009. 
Gollob, Jared A., Catherine J. Sciambi, Zhiqing Huang, and Holly K. Dressman. 2005. “Gene 
Expression Changes and Signaling Events Associated with the Direct Antimelanoma Effect of 
IFN-γ.” Cancer Research 65(19):8869–77. 
Gondek, D. C., L. F. Lu, S. A. Quezada, S. Sakaguchi, and R. J. Noelle. 2005. “Cutting Edge: 
Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-
Dependent, Perforin-Independent Mechanism.” The Journal of Immunology 174(4):1783–86. 
Grossman, William J. et al. 2004. “Differential Expression of Granzymes A and B in Human 
Cytotoxic Lymphocyte Subsets and T Regulatory Cells.” Analysis 104(9):2840–48. 
Guttman, Mitchell et al. 2009. “NIH Public Access.” 458(7235):223–27. 
Ha, Tai-You. 2011. “The Role of MicroRNAs in Regulatory T Cells and in the Immune Response.” 
Immune Network 11(1):11. 
Hawrylowicz, C. M. and A. O’Garra. 2005. “Potential Role of Interleukin-10-Secreting Regulatory 
T Cells in Allergy and Asthma.” Nature Reviews Immunology 5(4):271–83. 
			 83	
Heintzman, Nathaniel D. et al. 2007. “Distinct and Predictive Chromatin Signatures of 
Transcriptional Promoters and Enhancers in the Human Genome.” Nature Genetics 39(3):311–
18. 
Hindley, James P. et al. 2011. “Europe PMC Funders Group Analysis of the T Cell Receptor 
Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence 
for Conversion in Carcinogen-Induced Tumors.” 71(3):736–46. 
Hinterberger, Maria et al. 2010. “Autonomous Role of Medullary Thymic Epithelial Cells in 
Central CD4+ T Cell Tolerance.” Nature Immunology 11(6):512–19. 
Hodi, F. Stephen et al. 2010. “NIH Public Access.” N Engl J Med 363(8):711–23. 
Hon, Chung Chau et al. 2017. “An Atlas of Human Long Non-Coding RNAs with Accurate 5′ 
Ends.” Nature 543(7644):199–204. 
Hori, S. 2014. “Lineage Stability and Phenotypic Plasticity of Foxp3+ Regulatory T Cells.” 
Immunological Reviews 259(1):159–72. 
Hoskin, David W., Jamie S. Mader, Suzanne J. Furlong, David M. Conrad, and Jonathan Blay. 
2008. “Inhibition of T Cell and Natural Killer Cell Function by Adenosine and Its Contribution 
to Immune Evasion by Tumor Cells (Review).” International Journal of Oncology 32(3):527–
35. 
Hu, Guoming, Zhi’an Li, and Shimin Wang. 2017. “Tumor-Infiltrating FoxP3(+) Tregs Predict 
Favorable Outcome in Colorectal Cancer Patients: A Meta-Analysis.” Oncotarget 
8(43):75361–71. 
Joh, RI, Palmieri, CM, Hill, IT, Motamedi, M. 2015. “Regulation of Histone Methylation by 
Noncoding RNAs.” Biochimica et Biophysica Acta 1839(12):1385–94. 
Jonuleit, H. et al. 2001. “Identification and Functional Characterization of Human CD4(+)CD25(+) 
T Cells with Regulatory Properties Isolated from Peripheral Blood.” The Journal of 
Experimental Medicine 193(11):1285–94. 
Kajsa, Wing, Yasushi Onishi, and Paz Prieto-Martin. 2008. “CTLA-4 Control over Foxp3+ 
Regulatory T Cell Function.” Science 322(5899):9–12. 
Kapranov, Philipp et al. 2005. “Examples of the Complex Architecture of the Human 
Transcriptome Revealed by RACE and High-Density Tiling Arrays.” Genome Research 
15(7):987–97. 
Kearley, Jennifer, Jane E. Barker, Douglas S. Robinson, and Clare M. Lloyd. 2005. “Resolution of 
		
		 84	
Airway Inflammation and Hyperreactivity after in Vivo Transfer of CD4  +  CD25  +  
Regulatory T Cells Is Interleukin 10 Dependent.” The Journal of Experimental Medicine 
202(11):1539–47. 
Kim, Ryungsa, Manabu Emi, Kazuaki Tanabe, and Koji Arihiro. 2006. “Tumor-Driven Evolution 
of Immunosuppressive Networks during Malignant Progression.” Cancer Research 
66(11):5527–36. 
Kleinewietfeld, Markus et al. 2009. “CD49d Provides Access to ‘untouched’ Human Foxp3+ Treg 
Free of Contaminating Effector Cells.” Blood 113(4):827–36. 
Ko, Kuibeom et al. 2005. “Treatment of Advanced Tumors with Agonistic Anti-GITR MAb and Its 
Effects on Tumor-Infiltrating Foxp3  +  CD25  +  CD4  +  Regulatory T Cells.” The Journal of 
Experimental Medicine 202(7):885–91. 
Koebel, Catherine M. et al. 2007. “Adaptive Immunity Maintains Occult Cancer in an Equilibrium 
State.” Nature 450(7171):903–7. 
Kuczma, Michal et al. 2010. “Intratumoral Convergence of the TCR Repertoires of Effector and 
Foxp3+ CD4+ t Cells.” PLoS ONE 5(10). 
de la Rosa, Maurus, Sascha Rutz, Heike Dorninger, and Alexander Scheffold. 2004. “Interleukin-2 
Is Essential for CD4+CD25+ Regulatory T Cell Function.” European Journal of Immunology 
34(9):2480–88. 
Ladoire, Sylvain, François Martin, and François Ghiringhelli. 2011. “Prognostic Role of FOXP3+ 
Regulatory T Cells Infiltrating Human Carcinomas: The Paradox of Colorectal Cancer.” 
Cancer Immunology, Immunotherapy 60(7):909–18. 
Lathrop, Stephanie K. et al. 2011. “Peripheral Education of the Immnue System by Colonic 
Commensal Microbiota.” Nature 478(7368):250–54. 
Li, Mulin Jun et al. 2016. “GWASdb v2: An Update Database for Human Genetic Variants 
Identified by Genome-Wide Association Studies.” Nucleic Acids Research 44(D1):D869–76. 
Li, Yanmei et al. 2014. “The Possible Role of the Novel Cytokines IL-35 and IL-37 in 
Inflammatory Bowel Disease.” Mediators of Inflammation 2014. 
Liang, Bitao et al. 2008. “Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation 
Gene-3 Engagement of MHC Class II.” The Journal of Immunology 180(9):5916–26. 
Lieberman, Judy. 2003. “The ABCs of Granule-Mediated Cytotoxicity: New Weapons in the 
Arsenal.” Nature Reviews Immunology 3(5):361–70. 
			 85	
Lind, E. F., S. E. Prockop, H. E. Porritt, and H. T. Petrie. 2001. “Mapping Precursor Movement 
through the Postnatal Thymus Reveals Specific Microenvironments Supporting Defined Stages 
of Early Lymphoid Development.” The Journal of Experimental Medicine 194(2):127–34. 
Liu, Weihong et al. 2006. “CD127 Expression Inversely Correlates with FoxP3 and Suppressive 
Function of Human CD4 + T Reg Cells.” The Journal of Experimental Medicine 203(7):1701–
11. 
Liyanage, U. K. et al. 2002. “Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and 
Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma.” The Journal 
of Immunology 169(5):2756–61. 
Loebbermann, Jens et al. 2012. “IL-10 Regulates Viral Lung Immunopathology during Acute 
Respiratory Syncytial Virus Infection in Mice.” PLoS ONE 7(2). 
Luckheeram, Rishi Vishal, Rui Zhou, Asha Devi Verma, and Bing Xia. 2012. “CD4+T Cells: 
Differentiation and Functions.” Clinical and Developmental Immunology 2012. 
Ma, Huiying et al. 2014. “TGF-Β1-Induced Expression of Id-1 Is Associated with Tumor 
Progression in Gastric Cancer.” Medical Oncology 31(7). 
MacDonald, G., L. Shi, C. Vande Velde, J. Lieberman, and a H. Greenberg. 1999. “Mitochondria-
Dependent and -Independent Regulation of Granzyme B-Induced Apoptosis.” The Journal of 
Experimental Medicine 189(1):131–44. 
Maker, Ajay V, Peter Attia, and Steven A. Rosenberg. 2006. “NIH Public Access.” 175(11):7746–
54. 
Medical, Repatriation. 2005. “Antisense Transcription in the Mammalian Transcriptome.” Science 
309(5740):1564–66. 
Mellor, Andrew L. and David H. Munn. 2004. “IDO Expression by Dendritic Cells: Tolerance and 
Tryptophan Catabolism.” Nature Reviews Immunology 4(10):762–74. 
Mirza, Aashiq H., Simranjeet Kaur, Caroline A. Brorsson, and Flemming Pociot. 2014. “Effects of 
GWAS-Associated Genetic Variants on LncRNAs within IBD and T1D Candidate Loci.” 
PLoS ONE 9(8). 
Mori, Shunsuke, Anahid Jewett, Kaoru Murakami-Mori, Marta Cavalcanti, and Benjamin 
Bonavida. 1997. “The Participation of the Fas-Mediated Cytotoxic Pathway by Natural Killer 
Cells Is Tumor-Cell-Dependent.” Cancer Immunology Immunotherapy 44(5):282–90. 
Motoyoshi, Yasuhide et al. 2006. “Different Mechanisms for Anti-Tumor Effects of Low- and 
		
		 86	
High-Dose Cyclophosphamide.” Oncology Reports 16(1):141–46. 
Mougiakakos, Dimitrios, Aniruddha Choudhury, Alvaro Lladser, Rolf Kiessling, and C. Christian 
Johansson. 2010. “Regulatory T Cells in Cancer.” Advances in Cancer Research 107(10):57–
117. 
Mueller, Daniel L. 2010. “Mechanisms Maintaining Peripheral Tolerance.” Nature Immunology 
11(1):21–27. 
Murphy, Kenneth M. and Steven L. Reiner. 2002. “The Lineage Decisions of Helper T Cells.” 
Nature Reviews Immunology 2(12):933–44. 
Nakamura, Kazuhiko, Atsushi Kitani, and Warren Strober. 2001. “Cell Contact–Dependent 
Immunosuppression by Cd4 + Cd25 + Regulatory T Cells Is Mediated by Cell Surface–Bound 
Transforming Growth Factor β.” The Journal of Experimental Medicine 194(5):629–44. 
Natoli, Gioacchino and Jean-Christophe Andrau. 2012. “Noncoding Transcription at Enhancers: 
General Principles and Functional Models.” Annual Review of Genetics 46(1):1–19. 
Nguyen, Nghia et al. 2016. “TUMOR INFILTRATING LYMPHOCYTES AND SURVIVAL IN 
PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HHS 
Public Access.” Head Neck 38(7):1074–84. 
Nishikawa, Hiroyoshi and Shimon Sakaguchi. 2014. “Regulatory T Cells in Cancer 
Immunotherapy.” Current Opinion in Immunology 27(1):1–7. 
Nishikawa, Hiroyoshi and Shimon Sakaguchi. 2010. “Regulatory T Cells in Tumor Immunity.” 
International Journal of Cancer 127(4):759–67. 
Nizar, S. et al. 2009. “T-Regulatory Cell Modulation: The Future of Cancer Immunotherapy.” 
British Journal of Cancer 100(11):1697–1703. 
Oderup, Cecilia, Lukas Cederbom, Anna Makowska, Corrado M. Cilio, and Fredrik Ivars. 2006. 
“Cytotoxic T Lymphocyte Antigen-4-Dependent down-Modulation of Costimulatory 
Molecules on Dendritic Cells in CD4+ CD25+ Regulatory T-Cell-Mediated Suppression.” 
Immunology 118(2):240–49. 
Ohkura, Naganari et al. 2012. “T Cell Receptor Stimulation-Induced Epigenetic Changes and Foxp3 
Expression Are Independent and Complementary Events Required for Treg Cell 
Development.” Immunity 37(5):785–99. 
Ohkura, Naganari, Yohko Kitagawa, and Shimon Sakaguchi. 2013. “Development and Maintenance 
of Regulatory T Cells.” Immunity 38(3):414–23. 
			 87	
Ormandy, Lars A. et al. 2005. “Increased Populations of Regulatory T Cells in Peripheral Blood of 
Patients with Hepatocellular Carcinoma.” Cancer Research 65(6):2457–64. 
Pagani, Massimiliano et al. 2013. “Role of MicroRNAs and Long-Non-Coding RNAs in CD4 + T-
Cell Differentiation.” Immunological Reviews 253(1):82–96. 
Palmer, Ed. 2003. “Negative Selection - Clearing out the Bad Apples from the T-Cell Repertoire.” 
Nature Reviews Immunology 3(5):383–91. 
Pang, K. C. et al. 2009. “Genome-Wide Identification of Long Noncoding RNAs in CD8+ T Cells.” 
The Journal of Immunology 182(12):7738–48. 
Peggs, Karl S., Sergio A. Quezada, Cynthia A. Chambers, Alan J. Korman, and James P. Allison. 
2009. “Blockade of CTLA-4 on Both Effector and Regulatory T Cell Compartments 
Contributes to the Antitumor Activity of Anti–CTLA-4 Antibodies.” The Journal of 
Experimental Medicine 206(8):1717–25. 
Perrone, Giuseppe et al. 2008. “Intratumoural FOXP3-Positive Regulatory T Cells Are Associated 
with Adverse Prognosis in Radically Resected Gastric Cancer.” European Journal of Cancer 
44(13):1875–82. 
Qin, Zhihai et al. 2003. “A Critical Requirement of Interferon Gamma-Mediated Angiostasis for 
Tumor Rejection by CD8+ T Cells.” Cancer Research 63:4095–4100. 
Radoja, S., T. D. Rao, D. Hillman, and A. B. Frey. 2000. “Mice Bearing Late-Stage Tumors Have 
Normal Functional Systemic T Cell Responses In Vitro and In Vivo.” The Journal of 
Immunology 164(5):2619–28. 
Ranzani, Valeria et al. 2015. “Europe PMC Funders Group LincRNA Landscape in Human 
Lymphocytes Highlights Regulation of T Cell Differentiation by Linc-MAF-4.” 16(3):318–25. 
Read, Simon, Vivianne Malmström, and Fiona Powrie. 2000. “Cytotoxic T Lymphocyte–
Associated Antigen 4 Plays an Essential Role in the Function of Cd25 + Cd4 + Regulatory 
Cells That Control Intestinal Inflammation.” The Journal of Experimental Medicine 
192(2):295–302. 
Redmond, William L. and Linda A. Sherman. 2005. “Peripheral Tolerance of CD8 T 
Lymphocytes.” Immunity 22(3):275–84. 
Ren, X. et al. 2007. “Involvement of Cellular Death in TRAIL/DR5-Dependent Suppression 
Induced by CD4+CD25+regulatory T Cells.” Cell Death and Differentiation 14(12):2076–84. 
Sa, Gaurisankar et al. 2009. “GD3 an Overexpressed Tumor-Derived Ganglioside, Mediatesthe 
		
		 88	
Apoptosis of Activated but Not Resting T Cells.” Cancer Research 69(7):3095–3104. 
Sakaguchi, Shimon. 2004. “N <scp>aturally</Scp> A <scp>rising</Scp> CD4 + R 
<scp>egulatory</Scp> T C <scp>ells For</Scp> I <scp>mmunologic</Scp> S 
<scp>elf</Scp> -T <scp>olerance And</Scp> N <scp>egative</Scp> C <scp>ontrol 
Of</Scp> I <scp>mmune</Scp> R <scp>esponses</S.” Annual Review of Immunology 
22(1):531–62. 
Sakaguchi, Shimon, Dario A. A. Vignali, Alexander Y. Rudensky, Rachel E. Niec, and Herman 
Waldmann. 2013. “The Plasticity and Stability of Regulatory 
Tfile:///Users/Politano/Desktop/Hori2014.Pdf Cells.” Nature Reviews Immunology 13(6):461–
67. 
Sakaguchi, Shimon, Tomoyuki Yamaguchi, Takashi Nomura, and Masahiro Ono. 2008. 
“Regulatory T Cells and Immune Tolerance.” Cell 133(5):775–87. 
Salomon, Benoît et al. 2000. “B7/CD28 Costimulation Is Essential for the Homeostasis of the 
CD4+CD25+ Immunoregulatory T Cells That Control Autoimmune Diabetes.” Immunity 
12(4):431–40. 
Sasada, Tetsuro, Motohide Kimura, Yuka Yoshida, Michiyuki Kanai, and Arimichi Takabayashi. 
2003. “CD4+CD25+ Regulatory T Cells in Patients with Gastrointestinal Malignancies.” 
Cancer 98(5):1089–99. 
Sato, E. et al. 2005. “Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes and a High 
CD8+/Regulatory T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer.” 
Proceedings of the National Academy of Sciences 102(51):18538–43. 
Satpathy, Ansuman T. and Howard Y. Chang. 2015. “Long Noncoding RNA in Hematopoiesis and 
Immunity.” Immunity 42(5):792–804. 
Schaefer, C. et al. 2005. “Characteristics of CD4+CD25+ Regulatory T Cells in the Peripheral 
Circulation of Patients with Head and Neck Cancer.” British Journal of Cancer 92(5):913–20. 
Schoenbrunn, A. et al. 2012. “A Converse 4-1BB and CD40 Ligand Expression Pattern Delineates 
Activated Regulatory T Cells (Treg) and Conventional T Cells Enabling Direct Isolation of 
Alloantigen-Reactive Natural Foxp3+ Treg.” The Journal of Immunology 189(12):5985–94. 
Shevach, Ethan M. et al. 2006. “The Lifestyle of Naturally Occurring CD4+ CD25+ Foxp3+ 
Regulatory T Cells.” Immunological Reviews 212:60–73. 
Simpson, Tyler R. et al. 2013. “Fc-Dependent Depletion of Tumor-Infiltrating Regulatory T Cells 
			 89	
Co-Defines the Efficacy of Anti–CTLA-4 Therapy against Melanoma.” The Journal of 
Experimental Medicine 210(9):1695–1710. 
Sinicrope, Frank A. et al. 2009. “A Low Intraepithelial Effector (CD3+):Regulatory (FoxP3+) T-
Cell Ratio Predicts Adverse Outcome of Human Colon Carcinoma.” Gastroenterology 
137(4):1270–79. 
Starr, Timothy K., Stephen C. Jameson, and Kristin A. Hogquist. 2003. “P <scp>OSITIVE 
AND</Scp> N <scp>EGATIVE</Scp> S <scp>ELECTION OF</Scp> T C 
<scp>ELLS</Scp>.” Annual Review of Immunology 21(1):139–76. 
Strauss, L. et al. 2008. “Expression of ICOS on Human Melanoma-Infiltrating 
CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated 
Immune Suppression.” The Journal of Immunology 180(5):2967–80. 
Stuart E. Turvey, MB BS, DPhil and David H. Broide, MB ChB. 2006. “CHAPTER 14 Innate 
Immunity.” Immunology 125(2 Suppl 2):1–4. 
Sugiyama, D. et al. 2013. “Anti-CCR4 MAb Selectively Depletes Effector-Type FoxP3+CD4+ 
Regulatory T Cells, Evoking Antitumor Immune Responses in Humans.” Proceedings of the 
National Academy of Sciences 110(44):17945–50. 
Takahashi, Takeshi et al. 1998. “Immunologic Self-Tolerance Maintained by CD25+CD4+naturally 
Anergic and Suppressive T Cells: Induction of Autoimmune Disease by Breaking Their 
Anergic/Suppressive State.” International Immunology 10(12):1969–80. 
Tanaka, Atsushi and Shimon Sakaguchi. 2017. “Regulatory T Cells in Cancer Immunotherapy.” 
Cell Research 27(1):109–18. 
Taylor, Alison, Johan Verhagen, Kurt Blaser, Mübeccel Akdis, and Cezmi A. Akdis. 2006. 
“Mechanisms of Immune Suppression by Interleukin-10 and Transforming Growth Factor-β: 
The Role of T Regulatory Cells.” Immunology 117(4):433–42. 
Vesely, Matthew D., Michael H. Kershaw, Robert D. Schreiber, and Mark J. Smyth. 2011. “Natural 
Innate and Adaptive Immunity to Cancer.” Annual Review of Immunology 29(1):235–71. 
Vieira, Pedro L. et al. 2004. “IL-10-Secreting Regulatory T Cells Do Not Express Foxp3 but Have 
Comparable Regulatory Function to Naturally Occurring CD4 + CD25 + Regulatory T Cells.” 
Journal of Immunology (Baltimore, Md. : 1950) 172(10):5986–93. 
Vignali, Dario a, Lauren W. Collison, and Creg J. Workman. 2009. “How Regulatory T Cells 
Work.” Nature Reviews: Immunology 8(7):523–32. 
		
		 90	
Wall, Lucy, Frances Burke, Caroline Barton, John Smyth, and Fran Balkwill. 2003. “IFN-Gamma 
Induces Apoptosis in Ovarian Cancer Cells in Vivo and in Vitro.” Clinical Cancer Research : 
An Official Journal of the American Association for Cancer Research 9(7):2487–96. 
Wang, Dingzhi and Raymond N. Dubois. 2011. “NIH Public Access.” 10(3):181–93. 
Wang, Kevin C. et al. 2011. “A Long Noncoding RNA Maintains Active Chromatin to Coordinate 
Homeotic Gene Expression.” Nature 472(7341):120–26. 
Weiner, H. L. 2001. “Induction and Mechanism of Action of Transforming Growth Factor-Beta-
Secreting Th3 Regulatory Cells.” Immunol Rev 182:207–14. 
Welter, Danielle et al. 2014. “The NHGRI GWAS Catalog, a Curated Resource of SNP-Trait 
Associations.” Nucleic Acids Research 42(D1):1001–6. 
Whiteside, TL. 2013. “The Tumor Microenvironment and Its Role in Promoting Tumor Growth.” 
27(45):5904–12. 
Wilke, Cailin Moira, Ke Wu, Ende Zhao, Guobin Wang, and Weiping Zou. 2010. “Prognostic 
Significance of Regulatory T Cells in Tumor.” International Journal of Cancer 127(4):748–
58. 
Wolf, Anna Maria et al. 2003. “Increase of Regulatory T Cells in the Peripheral Blood of Cancer 
Patients Advances in Brief Increase of Regulatory T Cells in the Peripheral Blood of Cancer 
Patients 1.” 9(February):606–12. 
Workman, Cj, a L. Szymczak-Workman, L. W. Collison, and M. R. Pillai. 2009. The Development 
and Function of Regulatory T Cells. Vol. 66. 
Workman, Creg J., Andrea L. Szymczak-Workman, Lauren W. Collison, Meenu R. Pillai, and 
Dario A. A. Vignali. 2009. “The Development and Function of Regulatory T Cells.” Cellular 
and Molecular Life Sciences 66(16):2603–22. 
Zarek, Paul E. et al. 2014. “A 2A Receptor Signaling Promotes Peripheral Tolerance by Inducing T-
Cell Anergy and the Generation of Adaptive Regulatory T Cells A 2A Receptor Signaling 
Promotes Peripheral Tolerance by Inducing T-Cell Anergy and the Generation of Adaptive 
Regulatory T C.” 111(1):251–59. 
Zhang, Bin et al. 2012. “The LncRNA Malat1 Is Dispensable for Mouse Development but Its 
Transcription Plays a Cis-Regulatory Role in the Adult.” Cell Reports 2(1):111–23. 
Zhang, Yang et al. 2013. “Circular Intronic Long Noncoding RNAs.” Molecular Cell 51(6):792–
806. 
			 91	
Zhou, G. and H. I. Levitsky. 2007. “Natural Regulatory T Cells and De Novo-Induced Regulatory T 
Cells Contribute Independently to Tumor-Specific Tolerance.” The Journal of Immunology 
178(4):2155–62. 
Zou, Weiping. 2006. “Regulatory T Cells, Tumour Immunity and Immunotherapy.” Nature Reviews 
Immunology 6(4):295–307. 
 
